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1. Summary 
Despite the fact that neurological diseases of other etiologies receive more attention by the 
media, biomedical research and supporting foundations in industrialized countries, TBI still 
remains the leading cause of death in young individuals up to the age of 40 years. 
Research efforts in the past decade have focused on elucidating the role of the massive 
intracranial inflammatory response in the injured brain with regard to the neuropathological 
sequelae which are, in large part, responsible for the adverse outcome in neurotrauma 
patients. In the present study, we have investigated the effect of pharmacological 
complement inhibition at the C3 convertase (by Crry-Ig) on apoptosis, neuronal cell death 
and complement activation after experimental head injury, with a special focus on the anti-
apoptotic Bcl-2 protein and pro-apoptotic Bax protein. 
After trauma, the genes for C1-Inh and CD55 were significantly upregulated within 4h in 
the Crry-Ig-injected group, as compared to vehicle-injected controls. The genes’ 
expression was assessed using a semi quantitative two-step real-time RT-PCR. The CD59 
gene showed a slightly differing kinetic with a peak at 24 h, whereas the CD55 gene 
remained significantly elevated above the vehicle controls for up to 7 days after TBI. In 
contrast, the C1-Inh gene was significantly suppressed at the later time-points (24h and 7 
days) compared to vehicle-injected mice. These data suggest that Crry-Ig modulates its 
anti-complement effects not only by direct inhibition of C3 convertases. 
We identified a posttraumatic upregulation of Bcl-2 mRNA within 7 days, which was further 
induced in the Crry-Ig-treated group as early as 4h after trauma associated by an increase 
in intracerebral Bcl-2 expression, which was confirmed at the protein level by Western blot 
analysis. Interestingly, Bax mRNA was also provoked after introduction of Crry-Ig and Bax 
expression was increased but the Bax/Bcl-2 ratio was suggestible in favour of 
neuroprotection. This was confirmed by anti NeuN antibody stain which revealed 
neuroprotective signs in hippocampus and TUNEL histochemistry showing lower number 
of TUNEL positive cells in Crry-Ig treated mice vs. vehicle-treated mice.  
In conclusion, an effective pharmacological inhibition of the intracerebral complement 
activation, should provide a future avenue for successful attenuation of secondary brain 
injury, and may hopefully help reduce the high rate of neurological morbidity and 
delayed mortality in neurotrauma patients.  
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2. Introduction 
2.1 Traumatic Brain Injury  
Since several death and disability cases are reported after traumatic brain injury (TBI), it 
is regarded as a major public problem and the number of brain injuries sustained each 
year has been subjected to intense study with an overall incidence of 235 per 100 000 
persons per year[2]. 
Kraus and co-workers, depending on national and international studies calculated the 
average brain injury death rate at about 22 per 100,000 per year [3]. In industrialised 
nations, TBI represent the leading cause of death and residual logical impairment in 
young patients under the age of 40 years[4-9]. In the states of the Union approximately 
500,000 patients with TBI require hospitalization every year and mostly young people 
with a median age of 25 years are affected [4-6, 10, 11]. It’s also to be considered that 
about half of all trauma deaths in the United States involve significant injury to the 
brain[12]. The direct and indirect costs in the United States are estimated to be about 60 
billion dollars [13-15]. Despite advances in research and improved neurointensive care 
in the last decade, the clinical outcome of several head-injured patients is still poor and 
the mortality rate remains as high as 35-40% [4, 16, 17]. 
The follow-up study from Koponen and co-workers revealed that the up to 50-60% of 
the TBI patients are susceptible to psychiatric disorders, consequently underlying the 
high socio-economic impact of head injury [17]. 
The extent of residual brain damage is determined by the primary and secondary 
injuries. The primary injury to the central nervous system (CNS) is due to the 
mechanical forces applied to the skull and brain at the time of impact, leading to focal or 
diffuse injury patterns, whereby the secondary injuries are a result of complicated 
processes initiated by the primary insult and lead to blood brain barrier (BBB) 
dysfunction, induction of cerebral edema and intracranial hypertension [7, 16, 18-20]. 
Evidence of secondary brain injury has been found at autopsy in 70%-90% percent of all 
fatally head-injured patients[5]. These Secondary insults induce neuroinflammation by 
activation of the innate immunity, e.g. through complement activation, therefore triggering 
a profound host-mediated inflammatory response within the intracranial compartment[21-
26]. Among the crucial endogenous mediators of neuroinflammation are pro-inflammatory 
cytokines [27-31], chemokine [28] and complement anaphylatoxins [32-34] which induce 
chemotaxis of blood-derived leukocytes across the BBB into the subarachnoid space 
(SAS) [21, 35-37]. On one hand, these recruited inflammatory cells exacerbate and 
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perpetuate the inflammatory response in the CNS which further contribute to the 
development of secondary brain damage, e.g. through the oxidative burst of neutrophils 
associated with the release of proteolytic and neurotoxic enzymes[38-42] or hypoxia and 
hypotension which cause cerebral ischemia and reperfusion injuries[43]. On the other 
hand, the inflammatory response of the injured brain seems to induce beneficial effects as 
well, in terms of post-traumatic local induction of neurotrophic factors[44, 45]. Clinical and 
experimental studies have revealed that pro-inflammatory cytokines, such as interleukin 
(IL)- 1 [44, 46-48], IL-6[49, 50] and IL-8[51] are able to induce the production of the 
neurotrophin nerve growth factor (NGF) within the injured CNS. The net balance between 
detrimental and beneficial aspects of cerebral inflammation after TBI remains to be 
elucidated[27, 30, 47]. The expanding knowledge of the basic cellular and molecular 
mechanisms responsible for the inflammatory response of the injured brain has evoked 
new therapeutic approaches for head-injured patients[16, 52-56]. However, no efficacious 
pharmacotherapy has been developed for patients with severe TBI to date[5, 45, 57, 58]. 
As long as we can not influence the primary injury, the main target in the treatment of 
patients is the optimization of therapy to reduce the secondary injury. The aim of the 
experimental traumatologie is to develop, try and prove the effect of the potentially 
neuroprotective substances which would influence this process. 
 
2.2 Inflammatory brain response after trauma    
A traumatic impact to the brain stimulates metabolic and inflammatory processes which 
exacerbate the primary traumatic injury to neurons, leading to secondary brain damage 
[7, 24, 26, 54, 59]. The primary injury is the mechanical force applied to the skull 
causing local or diffuse brain injury , such as diffuse axonal injury (DAI), cerebral 
contusion, laceration of the neurons and intracranial bleeding [10, 16, 60-63]. The 
metabolic and immunological reaction leads to an extended intracranial inflammatory 
process and secondary injury which is believed to be responsible for the poor outcome 
after TBI [64]. This secondary brain injury occurs as a consequence of complicating 
processes initiated by the primary injury  and is characterized by neuroinflammation, 
ischemia/reperfusion injuries, cerebral edema, intracranial hemorrhage, and intracranial 
hypertension (Fig. 1) [65, 66]. The development of brain edema as a result of the 
secondary injury plays a big role in the poor prognosis after sever TBI [18, 67]. The 
neuroinflammatory reaction leads to a secondary cerebral ischemia which increases the 
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inflammatory reaction and cell death [68]. The early hypoxia and hypotension are as 
well important risk factors “lethal duo” for the exaggeration of the immune reaction by 
significantly decreasing the extent of brain oxygenation and cerebral perfusion due to 
shock and pulmonary injuries[43, 62, 69]. Additionally the peripheral injuries like open 
fractures could activate the immune defense and boost the inflammatory reaction. 
Cerebral endothelial injury is a concomitant of head injury[70]. The mechanism is not 
yet clear but its thought to be a result of direct or indirect injury, such as impact on 
cerebral vessels, hemodynamic stress, hypoxia, cerebral ischemia, or brain edema [71].  
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Figure 1. Primary and secondary injuries after TBI. The primary injury is the mechanical force applied 
to the skull causing local or diffuse brain injury, the secondary brain injury occurs as a consequence and 
has a chemical and neurological components. It is characterized by neuroinflammation, 
ischemia/reperfusion injuries, apoptosis, necrosis, brain edema and atrophy. 
 
Cerebral endothelial injury or activation promotes the release of inflammatory cytokines 
such as tumor necrosis factor (TNF) and IL-1 [22, 25, 26, 30, 72, 73], and the 
promotion of an inflammatory process in the cerebral endothelium may amplify the 
endothelial injury or activation[74]. This contributes to the BBB damage, since these 
cytokines have been shown to induce BBB dysfunction and intracranial inflammation in 
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a variety of experimental models [75-77]. This BBB disturbance lead to passive leakage 
of serum proteins into the intrathecal compartment [78-82]. Injured endothelial cells lose 
their ability to maintain a balance between coagulation and anticoagulation factors, to 
regulate the tone of smooth muscle, and to control vascular permeability. Increased 
vascular permeability in the cerebral parenchyma may result in delayed traumatic 
intracerebral hematoma[71], induction of vasogenic brain edema, leading to increased 
intracranial pressure (ICP) and decreased cerebral perfusion pressure (CPP), thus 
aggravating cerebral ischemia and the concomitant pathophysiological events [80].  
The CNS has often been considered an “immunologically privileged site”, this 
assumption being based on the absence of lymphatic drainage and the unique type of 
endothelium forming the BBB. There is no doubt that the brain differs significantly from 
other tissues in its responses to pathogenic challenges. Infection or inflammation elicits 
rather different responses in the brain to those in other tissues. This is most evident in 
leukocyte recruitment, which is rapid in many systemic organs, but modest and delayed 
in the brain [83]. Post-traumatic, blood-derived leukocytes are attracted across the BBB 
into the Subarachnoid space (SAS) [21, 26], microglia and blood-derived macrophages 
are activated by CNS damage or infection, and are recruited rapidly to the site of insult 
[83]. The presence of damaged cells and debris causes ramified resting microglia to 
transform into rounded migratory macrophages and produce cytokines and trophic 
factors that can exert damaging or protective effects on neighbouring cells [83]. The 
recruitment of neutrophils into the CNS is particularly important for the inflammatory 
response of the injured brain, since neutrophils have been shown to significantly 
contribute to host tissue damage by release of proteolytic enzymes and reactive oxygen 
intermediates [42, 84].  
The data suggest that, even under normal conditions, there is a moderate traffic of 
hematogenous cells through the BBB [85, 86]. The presence of astrocytes and microglia 
that embody the immune function, and the restrictive BBB, which is also known to 
possess immune functions, argue strongly for the unique immune status of the CNS 
[87]. Neurones, astrocytes, microglia and oligodendrocytes can produce inflammatory 
mediators, and cytokine receptors are expressed constitutively throughout the CNS, 
albeit at low levels. The constitutive expression of genes encoding cytokines and their 
receptors in the brain suggests that cytokines may contribute to normal physiological 
functions of the CNS [83]. It is now clear that the CNS is characterized by only a partial 
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immune privilege, in terms of downregulation and suppression of many aspects of the 
immune function in comparison with other organs [88]. 
Experiments with T-cell lines specific for CNS antigens have led to the surprising 
conclusions that the CNS is routinely surveyed by activated T-lymphocytes that can 
cross the BBB, and that astrocytes play a major part in the initiation and subsequent 
regulation of the intracerebral immune response [89, 90]. Since microglia cells have 
been shown to produce inflammatory mediators (cytokines), acting as antigen-
presenting cells for T-lymphocytes, these cells may play a fundamental role in the 
induction and maintenance of the inflammatory process in the CNS following a closed 
head injury [91, 92]. 
Induction of programmed cell death (PCD; apoptosis) in neurons has been 
demonstrated in experimental models of TBI[93-96] . In addition, mediators of PCD, 
such as soluble Fas, soluble Fas ligand (FasL), and caspase-3, have been detected in 
elevated amounts in the CSF of TBI patients[97-99]. Fas is of particular interest 
because it belongs to the TNF receptor superfamily; both share common steps of the 
downstream pathway, including the activation of caspases, pivotal factors in 
programmed cell death. Fas and FasL have been shown to be expressed on mouse 
neurons after experimental TBI[100] and their expression overlaps with neurons 
undergoing posttraumatic cell death [101] 
 
2.3  Cytokines and brain injury   
Cytokines are low molecular weight proteins which act as mediators of ‘‘communication’’ 
between leukocytes, bridging innate and adaptive immune responses. Pro-inflammatory 
cytokines, such as TNF and the IL-1b, -6, -8, -12, -15, and -18 have been described as 
potent inflammatory mediators induced by traumatic tissue injuries [102-104]. 
The TBI is believed to induce the local synthesis of cytokines by resident cells in the 
CNS [28, 30, 105-107] and to activate the innate immunity through the activation of the 
complement system [108] within seconds to minutes. The complement anaphylatoxins 
C3a and C5a triggers the induction of high potent pro-inflammatory cytokines, e.g. IL-1 
or TNF. A delayed activation of other pro-inflammatory cytokines e.g. IL-6, IL-18 and 
chemokines occurs within hours to days intracranially [48,109]. Cytokines can also 
cross the BBB, probably either by active transport or through leaky regions of endothelia 
when the BBB is compromised by a pathological condition [83]. Therefore the CNS is 
liable for affection by central as well as peripherally produced inflammatory mediators. 
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These mediators lead to the inflammatory reaction within the injured brain known as 
neuroinflammation [63]. Clinical studies have demonstrated elevated levels of TNF, IL-
6, and soluble IL-6 receptor in CSF and serum from head trauma patients [110-115]. 
Elevated levels of IL-12 and IL-18, pro-inflammatory cytokines with IFN (interferon) - 
modulating properties were also demonstrated in human CSF of patients with severe 
TBI[116, 117] 
The proinflammatory cytokines IL-1, IL-1α und IL-1 are significant mediators for the 
intracranial inflammatory response [48, 83, 107, 118, 119]. The signal transduction 
takes place through the 80 kDa- IL1 membrane Receptor (IL-1R) in which the 
competitive and high selective antagonist IL-1 Ra binds [120]. Normally IL-1α  and IL-1  
are hardly detected in brain[119]. Following trauma there is a fast induction of  IL-1α  
and IL-1gene expression in the glia cells as well as neurons and the cerebral vascular 
system’s endothelial cells [48, 119, 121-124]. IL-1 has a wide pro inflammatory effect 
which includes the induction of the central complement factor C3, nitrogen oxide 
synthase (NOS), the cyclooxygenase-2(COX-2) and other pro-inflammatory cytokines 
(e.g. IL-6 and IL-8) through multiple immune competent central and peripheral cells 
(Fig. 2) [48, 119, 125, 126]. An experimental study using trasgenetic mice with IL1Ra 
over expression showed that the inhibition of IL-1 lead to significant improvement of the 
neurological outcome following TBI [120]. The determining action of IL-1 is the induction 
of apoptosis in the CNS [118, 127]. Another indirect function of IL-1 is the induction of 
vascular endothelial growth factor (VEGR) [128], which is an important mediator in the 
post traumatic brain edema [129] (Fig. 2). In this way, IL-1 contributes through different 
molecular events to the cell death in the affected brain.  
TNF can be considered a major pro-inflammatory cytokine with an optional capacity to 
induce apoptosis [130]. TNF can be active both as a membrane integrated [130] and a 
soluble molecule after its processing by the metalloprotease TACE (TNFα-converting 
enzyme) [131]. This cytokine is reported to have both deleterious and protective actions 
in neurons, and these opposing effects may be explained by the existence of two 
distinct TNF-signaling pathways mediated by two receptors, p55 and p75 (Fig. 2) [73]. 
The p75 in the brain contains TRAF (TNF receptor-associated Factors)-interacting 
motifs that recruit TRAFs and thus directly activate the same intracellular pathways as 
IL-1 [132]. Activation of p55 initiates signals leading to neuronal apoptosis [133]. In the 
CNS, resident macrophages, astrocytes and microglia are able to synthesize TNF, 
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which seems to be proinflammatory during the acute phase of CNS inflammatory 
responses, but immunosuppressive during the chronic phase [83]. The duality of the 
role of TNF has been elegantly demonstrated in mice lacking this cytokine: acutely 
after cortical impact injury, the TNF knockout mice show less behavioural impairment 
than the wild-type controls, but while the wild-type mice recovered in the weeks 
following injury, the knockout mice did not, remaining significantly impaired both in 
terms of histological damage and behaviour [134]. These divergent activities may arise 
from the existence of two TNF receptors. 
 
Figure 2. The release of cytokines after TBI. TBI induces the local synthesis of cytokines in CNS. The 
proinflammatory cytokines IL-1, IL-1α und IL-1 have a wide pro inflammatory effect which includes the 
induction of C3, NOS, COX-2, IL-6, IL-8 and VEGR indirectly. See text for abbreviations  
 
The simultaneous pro- and anti-inflammatory effect mediated by many of the ‘‘key’’ 
inflammatory agents, such as TNF, implies that the irreversible pharmacological 
blocking may also lead to unexpected adverse events [30]. Due to central role of 
proinflammatory cytokines in the pathophysiology of severe injuries, a short-term 
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targeted inhibition in the early phase, e.g. by administration of neutralizing monoclonal 
antibodies with a very short half-life, may represent a further option [135-137]. 
 
2.4 The Complement system  
The complement system, a protein cascade involved in immune responses, consists of 
around 40 fluid-phase and cell membrane-associated proteins[108]. It appears to 
represent the ‘‘key’’ mediator of innate immune responses after trauma [138-141]. The 
activation products of the cascade contribute to the production of other inflammatory 
mediators, and can therefore promote tissue injury at sites of inflammation [83]. Once 
activated through one of three established pathways, complement plays a critical role in 
the elimination of invading pathogens by opsonisation for phagocytosis (C3b, C4b), 
chemotaxis of leukocytes (C3a, C5a), and by direct lysis of pathogens through the 
membrane attack complex (MAC, C5b-9).[140, 142-144]. C1q is an essential 
component of the classic pathway, whereas C4 is essential to both the classic and lectin 
complement pathways. The classic pathway is initiated when C1q interacts with natural 
antibody bound to neoepitopes present on injured tissue, whereas the lectin pathway is 
initiated by a complex formed by mannose-binding lectin (MBL), immunoglobulins and 
MBL-associated serine proteases (MBL-MASP) [145] (Fig. 3). Both activated C1 
complex and MBL-MASP complex may cleave C4 to C4a, C4b, and C4c. C4b and C2 
react to form C4b2a, a C3 convertase that cleaves and activates C3, the convergence 
point for all complement pathways [145]. The alternative pathway requires the 
spontaneous breakdown of C3 in serum and factor B to assemble a C3 convertase 
Complement (Fig.3). 
C3 is a key component in the activation of the complement system. The C3 precursor is 
a 185kD protein that is cleaved into an alpha (120kD) and a beta chain (75kD) linked by 
a disulfide bond. This mature C3 is further cleaved by C3 convertase to release C3a 
and C3b [146]. The anaphylatoxins C3a and C5a are potent chemo attractants for 
phagocytes and polymorphonuclear leukocytes (PMN, ‘‘neutrophils’’), and recruit these 
immune cells to the site of injury [147]. C3a is as well a potent vasoconstrictor and has 
been shown to be a promoter of inflammatory cytokines in human disease processes as 
diverse as cerebral ischemia [148] and Alzheimer’s disease [149]. The anaphylatoxins 
further induce degranulation of mast cells, basophils and eosinophils and mediate the 
hepatic acute-phase response [140, 143, 144]. The binding of C3a or C5a to receptors 
on oligodendrocytes and astrocytes may affect demyelination and scar formation 
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following CNS injury. The activation of C5aR by C5a peptide fragments has shown to 
trigger apoptosis in cortical and hippocampal cultures [150] and the activation of C3a 
and C5a receptors on astrocytes has been suggested to regulating scar formation and 
glial cell activation/chemotaxis [151, 152]. 
 
Figure 3. Activation of complement cascade via the classical, lectin or alternative pathways.   
C1q is an essential component of the classic pathway, whereas C4 is essential to both the classic and 
lectin Complement pathways. The alternative pathway requires factor B to assemble a C3 convertase 
Complement. 
 
Recently, it was discovered that C3a and C4a have direct antimicrobial activity, which 
provides an additional mechanism through which complement can kill microorganisms 
[153]. Finally, the generation of C5b by cleavage of C5 initiates the terminal 
complement pathway with MAC formation. The MAC forms through the self-association 
of C5b along with C6 to C9 and leads to the formation of a large membranolytic 
complex capable of lysing prokaryotic and eukaryotic cells. [140, 143, 144] by forming a 
pore in the phospholipids bilayer [154]. Clinical and experimental studies have 
demonstrated that complement activation occurs both locally, at the site of injury, as 
well as systemically after trauma.[34, 155, 156]. The systemic activation of the 
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complement cascade has been shown at the level of C3 in serum of trauma patients, 
and the extent of activation was correlated to the severity of injury [157, 158] 
 
2.5 Complement expression in the central nervous system  
Constitutive complement expression in the normal CNS is low, principally due to the 
tight separation between the vascular system and the intrathecal compartment by the 
BBB. However, a number of soluble complement components have been detected in 
the CSF under physiological conditions. Among these, complement proteins of the 
classical (C1q, C4) [159-161], and of the alternative activation pathway (C3, factor B) 
[161-165], as well as the terminal lytic pathway (C9) [166, 167] have been detected in 
normal CSF in constitutive low levels. Furthermore, complement components C1q, C3b 
and C3d are found in the vicinity of activated microglial, macrophage and astrocyte cells 
in the injured human brain [34]. C1q, C3, and other complement components 
contributed to brain edema and histopathology in models of ischemic and hemorrhagic 
brain injury [168, 169]. Increased cerebrospinal fluid C4a was associated with delayed 
ischemic neurological deterioration in patients with subarachnoid hemorrhage [170]. C4 
mRNA and protein were induced in peri-infarct tissue after permanent focal stroke in 
mice [152] and neonatal mice deficient in C1q had reduced cerebral ischemic tissue 
damage compared with wild type (WT) [168]. C1q gene expression was increased in 
contused rat brain after experimental TBI [171]. Experimental closed head injury in wild-
type C57BL/6 mice resulted in a systemic activation of the complement cascade, as 
determined by significantly elevated serum levels of the complement activation product 
C5a at all time-points assessed from 4 hours to 7 days [172]. 
Neurones, microglia, astrocytes and oligodendrocytes express complement proteins 
and receptors[33, 56, 173-177], where neurons are particularly susceptible to 
complement-mediated damage [83]. Moreover, glial cells are known to express 
receptors for C3a and C5a, and therefore are likely to take part in the complement-
mediated events following CNS injury [178, 179]. Several studies have demonstrated 
the deposition of C5b-9/MAC on neurons and oligodendrocytes after traumatic CNS 
injury [180, 181]. Furthermore, neutrophil infiltration and an accumulation of C3 in 
cortical and hippocampal brain sections have been shown after a moderate Fluid 
percussion injury (FPI) in rats [37].  
Proteins of the complement system are thought to originate mostly from the liver; 
however, previous studies have reported the expression or production of some 
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complement proteins by other cell types from the CNS [173, 182] and the immune 
system [183, 184]. 
The source of complement in normal CSF is either derived from passive leakage around 
the circumventricular organs, as demonstrated for C9[166] , or from intracerebral 
synthesis by resident cells of the brain[165, 173, 175, 176, 185]. The expression of 
complement proteins is prominently detected in the CNS 24 hours after TBI [145]  [186]. 
A recent study from Nguyen et al. using a spinal cord injury (SCI) model in rates 
showed that cultured PMNs (in vitro) expressed mRNAs encoding for C1q, C3 and C4, 
where as Complement Proteins C1q and C3 were detected in less than 30% of cultured 
PMNs [187] 3 days after CSI about 70% of the PMNs exhibited C1q and C3 which 
shows that PMNs might contribute to the elevated levels of Complement in CNS after 
trauma[187]. 
 
2.6 Strategies for therapeutic inhibition of complement activation  
C1 inhibitor has been shown to be therapeutically useful in a variety of animal models of 
inflammatory diseases, including gram-negative bacterial sepsis and endotoxin shock, 
suppression of hyperacute transplant rejection, and treatment of a variety of ischemia-
reperfusion injuries (heart, intestine, skeletal muscle, liver, brain)[188]. In Humans, the 
use of C1 inhibitor has shown promising results in ischemia-reperfusion injury where a 
randomized double-blind study of 80 similar patients compared C1 inhibitor treatment 
with a control group among patients with acute ST-elevation myocardial infarction who 
underwent emergency coronary artery bypass surgery, revealed reduced cardiac 
troponin I levels in the treated group, as well as significant improvement in mean arterial 
pressure, cardiac index, stroke volume and a variety of other clinical criteria [189].  
You et al showed recently that genetic inhibition of C4 in mice leaded to a reduction in 
post-injury motor deficits and a decreased brain tissue damage in a controlled cortical 
impact suggested [145]. 
Several early complement inhibitors have been investigated in experimental TBI models 
interfering with the cascade at the central level of the C3 convertases, where the three 
activation pathways merge [36, 190-194]. In a closed head TBI model, [192] reported 
that astrocyte overexpression of soluble complement receptor protein y (sCrry), a 
mouse-specific C3 convertase inhibitor, reduced posttraumatic blood– brain barrier 
damage and improved neurologic severity scores (including motor function, alertness, 
and physiologic behavior). Subsequently, we reported that systemic administration of 
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chimeric immunoglobulin G1-Crry (Crry-Ig) (Fig. 4) fusion protein also improved 
neurologic severity scores, and reduced hippocampal CA3/CA4 cell loss[191]. Other 
approaches were designed to inhibit the main inflammatory mediators of the 
complement cascade, such as the anaphylatoxin C5a [33, 186, 195, 196].  
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Figure 4. Simplified schematic of Complement inhibition in mice using Crry-Ig. Systemic 
administration of Crry-Ig after TBI showed improvement of the neurological outcome of mice. 
 
Post-TBI administration of progesterone had reduced the expression of both the C3a 
and C3b fragments of factor C3 without influencing its overall expression, suggesting an 
effect on C3 convertase [197] and increased CD55 gene expression at 48h post TBI 
[198]. A reduction in C3b [3] can inhibit further activation of the complement system and 
the resultant amplification of the inflammatory process.  
An immunemodulatory molecule, Vaccinia virus complement control protein (VCP), 
inhibit both classical and alternative pathways of the complement system and in so 
doing prevents cell death and inflammation [199]. Administration of VCP after moderate 
FPI showed a protective effect [200]. A recent study showed that VCP administration 
significantly influenced sensorimotor function recovery, but did not significantly improve 
the cognitive outcome after severe head trauma in Wistar rats. [201].  
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Some other studies have shown some controversy results showing the potentially 
protective role of complement. A previous study has shown that neural progenitor cells 
express receptors for complement anaphylatoxins C3a and C5a, and has suggested 
that complement promotes neurogenesis because C3 (-/-) deficient mice and mice 
lacking C3aR or mice treated with a C3aR antagonist had impaired ischemia-induced 
neurogenesis [202]. C5 deficient mice have shown increased intracerebral hemorrhage, 
worse neurological deficit and brain edema in comparison to C5 sufficient mice [203]. A 
recent study showed that MBL gene deficiency increases susceptibility to TBI in mice in 
Controlled cortical impact (CCI) trauma, where mice deficient in MBL had increased 
(almost two-fold compared to wild type) CA3 neuronal degeneration 6h after CCI.[204]. 
As a result novel and highly specific reagents such as exclusive inhibition of the 
alternative activation pathway.[172, 205-207] are currently under investigation in 
experimental models of traumatic injuries. 
 
2.7 Apoptosis/ programmed cell death (PCD)  
Apoptosis, the PCD means in Greek: “The fall of leaves in the Wind” [208, 209], and is 
known as a naturally occurring process of cell suicide that plays a crucial role in the 
development and maintenance of multicellular organisms by eliminating superfluous or 
unwanted cells [210-214]. This occurs during development, normal cell turn-over, 
hormone induced tissue atrophy and pathological processes such as neurodegenerative 
diseases [215],leading to death of millions of cells everyday in our bodies. Cells 
undergoing apoptosis show characteristic morphological changes, including shrinkage 
of the cell and its nucleus, plasma membrane blebbing, chromatin condensation and 
DNA fragmentation [210, 213]. 
All mammalian cells appear to express the basic machinery that mediates apoptotic cell 
death (e.g. a family of cysteine proteases, termed caspases), but the initiation of 
apoptosis is carefully regulated. Signals diverse as viral infection, extracellular survival 
factors, cell interactions and hormones may act to either suppress or promote the 
activation of “death program” [214]. 
Accumulating evidence strongly suggest that apoptosis contribute in a variety of 
neurodegenerative and neuroinflammatory diseases  [216-218]. Induction of cell death 
can be induced through two distinct mechanisms, which are differentiated by 
morphological characteristics and different patho-physiological pathways. On one hand, 
neurons can undergo necrotic cell death in an early phase after brain injury, due to 
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direct mechanical damage to membranes and cytoskeleton with consecutive 
disturbances in ionic homeostasis and energy metabolism due to decrease intracellular 
ATP-levels. On the other hand, neuronal apoptosis/PCD occurs as an active process 
involving protein synthesis of endogenous nucleases. Physiological apoptotic cell death 
is crucial tissue remodelling and development and it is characterized by maintenance for 
of the cellular membrane integrity, DNA fragmentation, chromatine condensation and 
cell shrinking with ultimative degradation of the cell into membranous vesicles. 
Apoptotic cell bodies are then rapidly phagocytozed by immunocompetent cells [210-
213]. Distinct signalling pathways of PCD have been described as intrinsic and extrinsic 
pathways of apoptosis (Fig. 5) [213]. While the intrinsic pathway is characterized by 
mitochondrial release of cytochrome C (Cyt c) into the cytosol and consecutive 
activation of caspases which ultimately lead to apoptotic cell death [219], the extrinsic 
pathway is mediated by extracellular “death factors”, such as FasL,TNF and other 
members of the TNF-family, IL-18 and granzymes which correspond to enzymes 
released by natural killer(NK) cells[220]. Ligand-binding to specific receptors expressed 
on cell surfaces (“death receptors”) activates intracellular “death domains” which are 
capable of triggering a cascade of cysteine proteases (caspases;IL-1-converting 
enzyme related enzymes) whose activity is essential for almost all pathways of 
apoptosis [213, 214, 221] . 
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 2.8 The role of Apoptosis in Neurotrauma 
In the past years, the mechanisms of neuronal cell death after TBI (Fig. 6) have 
received increased attention. It has been recognized that the process leading to brain 
parenchymal destruction and neuronal loss persist for a long period after trauma, based 
on studies in humans as well as in experimental brain injury models in rodents [94, 98, 
99, 222, 223].  
 
Figure 6
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. Proposed mechanisms of brain damage after traumatic brain injury. Primary brain injury 
due to the traumatic impact and resulting tissue damage leads to necrosis. Secondary brain injury is 
initiated by the inflammatory response and by intracellular activation of the apoptotic cascade, e.g. by 
ligand binding FasL to the Fas receptor. (See text for details) 
  
Neuronal cell death is a very complex phenomenon possibly resulting from different 
events occurring simultaneously in response to trauma. Among these, the release of 
EAA, leading to excitotoxic cell death, and of reactive oxygen species (ROS) which 
induce mitochondrial dysfunction and consequent energy failure have been well 
recognized as causes of delayed neuronal death [224]. Evidence for apoptotic as well 
as necrotic cell death of neurons, astrocytes and EC has been reported in the brain of 
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rats subjected to fluid percussion injury and controlled cortical impact injury [93 , 225-
227]. Within the cascade of apoptotic cell death, the involvement of the Fas/FasL-
system, the tumour suppressor gene p53, caspases and anti-apoptotic factors of B-cell 
leukemia/lymphoma-2 (Bcl-2) family  has been reported in various experimental brain 
injury models as well as in human TBI [94, 97-99, 101, 222, 223, 228-230]. Although 
apoptosis has been defined as a process of cell death independent from 
immunoactivation, apoptotic neuronal cell death has been observed at time-points 
which correspond to the elevation of intracerebral cytokine production after 
experimental head injury in mice[101, 105]. Whether or not inflammatory mediators can 
be considered as potential factors which mediate neuronal cell death after brain injury is 
still awaiting further experimental evidence. In a model of controlled cortical impact 
injury, Fas expression has been identified on astrocytes and neurons, while FasL 
increased also in microglial cells and both stainings overlapped with the regions 
displaying the highest distribution of TUNEL (terminal deoxynucleotidyl transferase 
(TdT)-mediated dUTP nick end labeling) positive cells, as a sign of PCD-mediated DNA 
fragmentation [101]. 
Neurotoxin- or ischaemia-mediated apoptotic death was preceded by increased Bax 
mRNA and protein, and decreased expression of Bcl-2 in cells that are destined to die 
[231], while an Bcl-2 immunoreactivity was observed in neurons, glia and EC that 
survived focal ischemic injury[232]. Similarly, increased expression of Bcl-2 has been 
observed in neurons that survive the traumatic insult both in rat and in brain-injured 
humans [229, 233], while Bax was observed to translocate to the nucleus of apoptotic 
cells following experimental brain injury [227]. Increased expression of Bax and 
decreased expression of Bcl-XL have been reported at the site of injury in rat brain [234, 
235]. An increased ratio of Bax/Bcl-2 has also been reported in rat cortex following TBI 
[236]. Alternatively, recent studies have suggested that decreases in intracellular Bcl-2 
immunoreactivity, with little to no change in Bax proteins, in injured brain regions may 
precede cell death following experimental brain trauma [94, 236]. Transgenic mice 
overexpressing the human Bcl-2 protein exhibited significantly less neuronal loss in the 
injured cortex and hippocampus following experimental TBI, lending support to the idea 
that Bcl-2 may participate in the neuronal cell death following TBI [237, 238]. A pro-
apoptotic member of the Bcl-2 family, Bid, has also been implicated in trauma-induced 
cell death in vivo—proteolysis of Bid preceding its translocation to the mitochondria has 
been demonstrated in the injured cortex [239].  
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Further downstream in the apoptotic cascade, the activation of poly-ADP-ribose-
synthase, an enzyme mediating DNA repair, has been demonstrated early (30 min) in 
the injured cortex and has been shown to be cleaved later on (one week) and inhibit 
delayed repair of damaged DNA [240]. 
After experimental axonal injury, the alterations caused by tear-shearing injury of axonal 
membrane lead to Ca++ influx, cytoskeleton changes and mitochondrial swelling which 
are determined by the opening of the membrane permeability transition pores (PTP). 
The expression of Cyt c and caspase-3 have been associated to brain regions with 
greater mitochondrial damage, thus, converging the cascade of apoptotic cell death and 
energy failure [241]. Clinical studies revealed that sFasL, sFas, and caspase-3 activity 
are elevated in CSF of severely head injured patients [97-99]and that sFasL levels in 
CSF correlated significantly with severity on brain injury [97]. In addition, the prolonged 
intrathecal release of sFas correlated with the release of neuron-specific enolase as a 
marker of neuronal cell death, implying that activation of Fas-mediated PCD after 
neurotrauma may contribute to prolonged and delayed neuronal cell death [99]. In brain-
injured children, Bcl-2 was elevated in CSF and in brain tissue samples from patients 
undergoing emergent decompressive craniectomies, suggesting that Bcl-2 may 
participate in the regulation of cell death in paediatric neurotrauma [230]. Further more 
the increase in Bcl-2 detected in  surviving patients suggest a protective role for this ant-
apoptotic protein after TBI [230]. Inflammation seems at least to modulate apoptosis 
indirectly, as pro-inflammatory cytokines have been shown to enhance the constitutive 
expression of Fas and FasL by cultured human astrocytes and astroglia [101, 242]. In 
addition, FasL-bearing astrocytes have been shown to undergo apoptosis in vitro and to 
induce apoptosis of co-cultured lymphocytes, suggesting that this mechanism of cell 
death may also occur after brain injury in neuronal cells [101, 242]. The exact 
mechanism of complement-mediated interaction with PCD remain unknown, thus 
linkage between innate immunity and apoptotic events need to be further investigated 
[243].  
 
2.9 The BCL-2 Gene Family and its role in cell death regulation 
Bcl-2 was identified originally as a novel pro-survival oncogene in B-cell lymphoma 
where, by chromosomal translocations, it was moved into juxtaposition with strong 
enhancer elements in the immunoglobulin heavy-chain locus  [244, 245]. The result was 
the deregulation of the translocated Bcl-2 gene and the overproduction of Bcl-2 mRNA 
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and its encoded protein. On this consideration, Bcl-2 has been established to be a 
proto-oncogene that prolongs cell survival by inhibiting apoptosis. Subsequent studies 
have demonstrated that Bcl-2 can prevent or delay apoptosis induced by a large variety 
of stimuli in many cell types [246, 247], but the mechanism of its protective action has 
remained unclear. Soon after the discovery of Bcl-2, a family of proteins emerged that 
share with it differing degrees of homology and function [248]. Several hypotheses have 
been proposed to explain the anti-apoptotic function of Bcl-2. The Bcl-2 family of 
proteins may act as a regulator for Ca2+ homeostasis [249]  or as an antioxidant [250]. 
In addition, Bcl-2 family of proteins plays a major role in regulating the intrinsic or 
mitochondrial apoptotic pathway, whereby Bax translocation from the cytosol to the 
mitochondria triggers the release of Cyt c to the cytosol [251-254]. Cyt c binds to 
apoptosis activating factor 1 (Apaf-1) in the cytosol (Fig.7) [255], which allows for the 
recruitment and subsequent activation of caspase 9, an initiator caspase, in this 
apoptosome complex [256]. Activation of caspase 9 in turn induces downstream 
activation of caspase 3, an effector caspase that when activated cleaves proteins such 
as poly ADP-ribosyl DNA polymerase (PARP), a DNA repair enzyme that when 
inactivated leads to apoptotic nuclear fragmentation [257]. 
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Figure 7. Model of apoptotic and survival signaling pathways involving the Bcl-2 members
(Left) Activation of apoptotic pathways involving the TNF/Fas cell surface receptor lead
caspase-8. Caspase-8 cleaves cytosolic p22 BID generating a p15 carbo
translocates to the mitochondria resulting in the release of Cyt c. Released Cyt c activates 
in turn activates a downstream caspase program. (Right)A death stimulus (IL-3 deprivatio
translocation of Bax to the mitochondria where it is integral membrane and cro
homodimer. (Center) Activation of the NGF or PDGF receptors mediates the acti
the phosphorylation of BAD at Ser-136. Activation of the IL-3 receptor mediates the 
mitochondrial-based protein kinase (PKA) holoenzyme, resulting in the phosp
112. Phosphorylated BAD is sequestered to the cytosol by the phosphoserine-binding
 
Bcl-2 may prevent the release of the mitochondria activators of the cytosolic caspases,
which eventually mediates apoptosis-specific intracellular proteolysis [246]. The 
initiation and maintenance of Bax-dependent apoptosis has been studied extens
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of the mitochondrial transmembrane potential that occurs during apoptosis [247]. In 
addition, the initiation of Bcl-2 family-dependent apoptosis depends not only on the 
relative expression levels of its pro- versus anti-apoptotic members but also on death 
stimulus and its severity [248, 255] (Fig. 8). 
By various biochemical, genetic, and molecular techniques, numerous homologous of 
the Bcl-2 have been identified in vertebrates, forming a Bcl-2 family of proteins. This 
family includes proteins, which can promote either cell survival, such as Bcl-2, Bcl-XL, 
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Mcl-1, A1, Bcl-W[258] or cell death, like Bax, Bak, Bcl-XS, Bok [246]. The relative 
amounts or equilibrium between these pro- and anti-apoptotic proteins influence the 
susceptibility of cells to a death signal. 
 
 
Figure 8. Schematic model of mammalian cell death pathway. [255]. A major checkpoint in the 
common portion of this pathway is the ratio of pro-apoptotic (Bax) to anti-apoptotic (Bcl-2) members. 
Downstream of this checkpoint are two major execution programs: the caspase pathway and 
mitochondria dysfunction. Mitochondrial dysfunction includes a change in the mitochondrial membrane 
potential (m), production of ROS, opening of the PTP, and the release of the intermembrane space 
protein, Cyt c. Released Cyt c activates Apaf-1, which in turn activates a downstream caspase program. 
Activated caspases can also affect the function of mitochondria. Caspases could be activated through 
Apaf-1/ Cyt c or directly by activation of cell surface death receptors. Caspases (e.g., caspase-3) are 
activated by two cleavage events that occur between the prodomain and the large subunit (p17) and 
between the large subunit and the small subunit (p12). The activated caspase, composed of two large 
and two small subunits, cleaves death substrates (e.g., PARP), which ultimately leads to cell death. 
 
Unrelated to their role in apoptosis, all Bcl-2 family members are characterized by 
containing at least one of four conserved Bcl-2 homology (BH) domains, designated 
BH1-BH4, which correspond to -helical segments [258]. In general, the anti-apoptotic 
members show sequence conservation in all four domains (Fig. 9), while the pro- 
apoptotic molecules are characterized by loosing the sequence conservation of the first 
-helical segment, BH4[259]. The BH3 domain is presumed as a critical death domain 
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in the pro-apoptotic members. This concept is supported by "BH3-domain-only" 
members (Fig. 9), who show sequence homology only within the BH3 domain and to 
date, are all pro-apoptotic [260]. The Bcl-2 protein is a membrane protein that is 
localized to the outer mitochondria membrane, endoplasmic reticulum membrane, and 
nuclear envelope, whereby it’s NH2-terminal is facing the cytosol. As many other 
members of its family, Bcl-2 has a hydrophobic domain at COOH-terminal (TM domain, 
see (Fig. 9)) that allows the insertion of the protein into the cytosolic face of the 
intracellular membranes [261]; this intracellular localization is important for their 
function. 
 
Figure 9. Schematic representation of the structural features of anti-apoptotic and pro-apoptotic
Bcl-2 proteins[259]. The structures of proteins are presented in linear forms, BH1-4 indicate the
homologue domains and TM the carboxy-terminal hydrophobic transmembrane domain. The Bcl-
proteins include: anti-apoptotic proteins (Bcl-2, Bcl-XL, Mcl1, A1, Bcl-W) with all four BH and the TM 
domains, pro-apoptotic proteins (Bax, Bak, Bok) having TM, and BH13 domains but without BH4 domain,
and pro-apoptotic ligands possessing only the BH3 domain with (Bik, BNIP) or without (Bad, Bid, Bim, 
EGL-1) TM. 
 
An important feature of the members of Bcl-2 family is their ability to form homo- as well 
as heterodimers, suggesting neutralizing competition between these proteins. Thus, 
Bcl-2 (a 239 aminoacids protein, 26 kDa) forms heterodimers with Bax, a proapoptotic
 
 
2 
 
 
protein with ~ 21% aminoacid identity with Bcl-2 [258]. In addition to Bax, several other 
genes have been reported to encode proteins having sequence homology with Bcl-2 
and capacity to form heterodimers with it. Among these, Bcl-X is able to generate two 
proteins through an alternative splicing mechanism: Bcl-XL (longer form) and Bcl-XS 
(shorter form). Bcl-XL is a 241 aminoacids protein that suppresses the cell death, 
having 43% sequence identity with Bcl-2, while Bcl-XS, in which a 63-aa region (aa 126-
188) found in Bcl-XL is missing, functions as a proapoptotic protein [258]. Another Bcl-2 
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homologous is Mcl-1, which shares ~ 35% sequence identity with Bcl-2 over a region of 
~ 140-aa [262]. Until now, it was not clearly demonstrated whether Mcl-1 is able to 
interact with Bcl-2, or functions in the regulation of cell death. 
Regarding the intracellular localization of Bcl-2 family members, in the absence of a 
death signal, pro- and anti-apoptotic Bcl-2 proteins are localized to distinct intracellular 
compartments, providing important clues for their function [263]. Anti-apoptotic 
members are initially integral membrane proteins found especially in the mitochondria, 
endoplasmic reticulum, and nuclear membranes [264]. The large majority of the pro-
apoptotic proteins are localized to the cytosol, but following a death signal, it appears 
that they undergo a conformational change that enables them to target and integrate 
into mitochondria outer membrane and to function as pro-apoptotic proteins [251, 265-
267]. 
Bcl-2 is the prototypical member of the Bcl-2 Family [268]. Bcl-2 mRNA and protein are 
present at relatively high levels in the developing nervous system and decline 
significantly in the postnatal brain [269, 270]. Bcl-2 expression is maintained at relatively 
high levels in sensory and sympathetic neurons in the adult peripheral nervous system 
[270, 271]. The role of Bcl-2 in neuronal PCD has been examined using several 
experimental approaches. Trophic factor withdrawal-induced death of a variety of 
neuronal cell lines and primary neuron populations, an vitro model of target-dependent 
programmed cell death, is inhibited by Bcl-2 overexpression [272, 273]. Similarly, 
neuronal overexpression of Bcl-2 in transgenic mice increases the number of neurones 
in many brain regions by inhibiting naturally occurring neuronal death [273, 274]. These 
overexpression studies, however, only indicate a potential role for endogenous Bcl-2 in 
regulating PCD since other anti-apoptotic family members may play a more significant 
role in vivo. [275].  Targeted disruption of the Bcl-2 gene has indeed revealed selective 
effects of endogenous Bcl-2 expression on different neuronal populations. 
Despite high levels of Bcl-2 mRNA and protein expression in both neural precursor cells 
and in post-mitotic neurons in the embryonic brain, Bcl-2-deficient embryos show 
relatively normal nervous development and no significant increase in neuronal 
programmed cell death[275]. Bcl-2 deficient mice exhibit a profound loss of motor 
neurons, sympathetic neurons and sensory neurons during early postnatal life [276-
278]. Unlike neurons in the brain, these peripheral neuronal populations normally exhibit 
significant baseline Bcl-2 expression during the neonatal period [270]. The death of 
these neurons in Bcl-2 deficient mice occurs after the normal peak of PCD in these 
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populations, suggesting that Bcl-2 may play a role in maintenance of their survival 
rather than in regulating their PCD per se. [275].   
The pro-apoptotic molecule Bax was originally identified as a binding partner for Bcl-2 
[279]. Bax is expressed in both the embryonic and adult brain and can heterodimerize 
with Bcl-2, Bcl-XL, Mcl-1 and A1 [262, 279-281]. Current data suggest that Bax 
regulates Cyt c release from mitochondria perhaps via formation of the mitochondrial 
transition pore [254, 282]. Anti-apoptotic members of the Bcl-2 family may 
heterodimerize or hetero-oligomerize with Bax to inhibit Bax function. Targeted gene 
disruption of Bax has demonstrated an important role for Bax in triggering neuronal 
programmed cell death. 
In the developing nervous system, PCD of synapse-bearing neurons during a period of 
competition for target-derived neurotrophic support helps determine neuronal cell 
members. Bax-deficient mice exhibit markedly decreased neuronal PCD in a variety of 
sites including brainstem, cerebellum, dorsal root ganglia, hippocampus, and spinal 
cord, with resultant increased neuron numbers in these areas[283, 284]. This 
phenomenon is recapitulated in vitro in neonatal sympathetic neuron cultures. Following 
NGF withdrawal, wild-type sympathetic neurons exhibit redistribution of Cyt c from the 
mitochondria to the cytosol and undergo fairly rapid apoptotic death[283, 285]. In 
contrast, Bax deficient sympathetic neurons do not show increased cytosolic Cyt c and 
survive for weeks after NGF withdrawal [285]. Bax-deficient neurons under these 
conditions exhibit reduced soma size and axon diameter. Neuronal atrophy is also 
observed in vivo in some populations of Bax-deficient neurons, indicating that neurons 
“rescued” from PCD may not be completely normal [283, 284]. Interestingly, in certain 
models of trophic factor withdrawal-induced neuronal death, Bax may not play a critical 
role. For example, in NGF-deprived trigeminal neurons, Bax-deficiency delays, but does 
not prevent, cell death [286]. Also, in cultured chick sensory and ciliary neurons, Bax 
over-expression may have a pro-survival action following trophic factor withdrawal [287]. 
Bax may also play a role in regulating activity dependent neuronal apoptosis. Cerebellar 
granule neurons (CGNs) undergo apoptosis when cultured in non-depolarizing, serum-
free media, and Bax-deficient CGNs are protected from this apoptotic stimulus [288, 
289].  
Targeted disruptions of both Bax and Bcl-X revealed important roles for these Bcl-2 
family members in neuronal programmed cell death. To examine the potential 
interaction of Bax and Bcl-XL in neuronal cell death regulation, Bax/Bcl-XL deficient 
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embryos were generated. Bax, Bcl-XL dual-deficient embryos showed complete 
protection from Bcl-XL deficiency-induced neuronal apoptosis [290]. The 
neuroprotective  effect of Bax deficiency on Bcl-XL -deficient cells was also observed in 
vitro in primary telencephalic neuronal cell cultures [290]. Bax deficiency did not, 
however, rescue Bcl-XL-deficient mice from embryonic lethality, indication that Bcl-XL 
has both Bax-dependent and Bax-independent actions on different cell types [290]. 
Although Bax deficiency inhibits PCD in many neuronal populations, Bax-dependent 
death pathways also contribute significantly to nervous system morphogenesis. Like 
Bax-deficient mice, mice with targeted gene disruptions of caspase-9, apaf-1 and 
caspase-3 exhibit markedly reduced PCD. However, unlike Bax-deficient mice, a 
significant number of embryos with caspase-9, apaf-1 and caspase-3 gene disruptions 
also possess gross structural brain abnormalities, including neural precursor cell 
hyperplasia and forebrain exencephaly [291-294]. 
This conclusion requires caution, however, for several reasons. First, the 
neurodevelopemental effects of caspase-9, apaf-1 and caspase-3 gene disruption are 
incompletely penetrant and strain-dependent. For example, caspase-3 deficiency 
causes perinatal lethality and severe neurodevelopmental pathology in 129x1/SvJ mice. 
In contrast, the same gene disruption in C57BL/6J mice leads to minimal 
neuropathological abnormalities[295]. This result indicates that direct comparisons 
between gene disruptions on different or mixed genetic backgrounds are problematic. 
Second, Bcl-2 family members have overlapping actions, thereby raising the possibility 
that changes in the expression of other family members may compensate for Bax 
deficiency [275]. 
 
 29
3. Specific aims of this project 
 
3.1  Experimental Study 
Analysis of the pro and anti-apoptotic proteins (Bcl-2 and Bax) regulation following 
experimental TBI in mice (wild type, vehicle injected mice and Crry-Ig injected mice) 
using Western Blot. 
 
3.2  Experimental Study 
Assessment of the intracerebral expression of the Bcl-2 and Bax genes. A semi-
quantitative two-step real-time RT-PCR using murine-specific primers was utilized. 
  
3.3  Experimental Study 
Revealing of the Neuronal morphology, integrity and microarchitecture using a 
monoclonal antibody against the murine neuronal cell-marker NeuN. 
 
3.4  Experimental study 
Detection of Intracranial cell death in brain cells following experimental TBI in mice by 
the detection of DNA fragmentation with the terminal deoxynucleotidyl transferase 
(TdT)-mediated dUTP nick end labelling (TUNEL) technique. 
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4. Materials and Methods 
 
4.1 Chemicals 
Chemicals Company 
Acrylamid/Bisacrylamid (37, 5: 1) (Rotiphorese Gel) Roth 
Ammoniumpersulfat (APS) Roth 
Aprotinin  Sigma 
BCA Protein Assay Kit  Pierce 
-Mercaptoethanol Merck 
Bromphenol blue Biorad 
Coomassie Blue Roth 
Deionized water Biochrom AG 
DMSO (Dimethyl sulfoxide) Roth 
ECL solution (developing substrate) Amersham  
Ethanol Merck 
Glycerol Roth 
Glycine Serva 
Igepal CA-630 Sigma 
Isoflurane Forene 
Kaleidoscope Polypeptide Standards Biorad 
Leupeptin  Roche 
Methanol J.T.Baker 
Non-Fat Dry Milk Biorad 
PBS (Phosphate-buffered saline) Biochrom AG 
Pepstatin   Roche 
PMSF(Phenylmethanesulfonylfluoride) Sigma 
Ponceau S Sigma 
Precision Plus Protein Standards  Biorad 
Prestained SDS-Page Standard (Broad Range) Biorad 
SDS(Sodium Docecylsulfate) Sigma 
Sodium chloride Roth 
Sodium hydroxide  Roth 
TEMED Roth 
Tris (Base) Roth 
Tris-HCl Roth 
Tween-20 Sigma 
 
Table 2 shows all the chemicals used during the experiments and their producing company. 
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4.2 Other materials 
Materials Company 
Blue und Red Cap Tubes (50 ml) Falcon 
Cryo test tubes Falcon 
Disposables for cell culture (96 wells) Nunc 
Film cassette Kodak 
Film developing machine Kodak 
Filter paper 3MM Schleicher und Schuell 
Heparin syringe Becton Dickinson  
Hyper film Amersham 
Micro filter Nalgene 
Microliter syringe Hamilton 
nitrocellulose (Protran BA 83) Schleicher und Schuell 
PP-Tube Greiner bio-one 
Professional wipes Kimwipes 
Safe lock tubes Eppendorf 
Scalpel Feather 
Serological pipette Falcon 
Transparency film Tartan 
 
Table 3 Shows all the other materials used during the experiments and their producing company. 
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4.3 Laboratory equipment 
Laboratory equipment Company 
balance Scaltec 
Centrifuge (2k15) Sigma 
Centrifuge with JA25.25 rotor Beckman 
Dispersing tool (T18 basic) IKA works 
Dri Block (DB-2D) Techne Dri-Block 
Electronic pipette Neo Accupette 
Freezer (-20°C) Liebherr 
Freezer (-80°C) Bioblock Scientific 
Ice machine Ziegra 
Incubator Memmert 
Macro pipette controller Brand 
Magnitic stirrer  Hanna Instruments 
Micro plate reader Biorad 
Microbiological safe working bench Clean air 
Mini Electrophoresis model Biorad 
Mini Transfer model Biorad 
Mixer (Vortex Genie 2) Scientific Instuments 
Multi pipette Eppendorf 
PH meter Fischer Scientific 
Pipette Eppendorf 
Power supply (Powe Pac) Biorad 
Precision balance Denver 
Refrigerator (4°C) Bosch 
Scanner Hewlett Packard 
Shaker Edmid Bühler 
Table centrifuge (Micro 7) Fischer Scientific 
Water deionizing machine Millipore 
Waterbath Memmert 
 
Table 4 shows all the laboratory equipments which were used during the experiments and their producing 
company 
 
4.4 Antibodies 
4.4.1 Primary antibody 
A dilution series, in 3% or 5% (depending on the antibody) non-fat dry milk in PBS 
(phosphate-buffered saline) -Tween (0.05%) was performed for all antibodies used in 
this project. 
To detect the anti-apoptotic oncoprotein Bcl-2, a monoclonal mouse anti human Bcl-2 
(Santa Cruz Biotech. Inc, Santa Cruz, CA, U.S.A) was used at a dilution of 1:500 in 3% 
milk and incubated for 2:30h. The pro-apoptotic protein Bax was detected using a 
polyclonal rabbit anti human Bax- (Santa Cruz Biotech. Inc, Santa Cruz, CA, U.S.A) at 
a dilution of 1:200 in 5% milk and incubated for 1h.To detect the cytoskeletal protein -
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Actin a monoclonal anti-mouse antibody (Sigma, Saint Louis, Missouri, USA) was 
utilised and diluted 1:5,000 in 5% milk and incubated for 1h. 
 
4.5 Animals 
4.5.1 Breeding conditions 
All animals had been acclimatised several weeks before the experiments and were kept 
isolated from the external influences during the entire time course of the study in the 
Laboratory (Forschungseinrichtung für Experimentelle Medizin, Berlin, Germany). 
They were housed in groups of 10 per cage and separated into individual cages once 
they reach 25 g. They were bred in a specific pathogen-free (SPF) environment, kept 
under standard conditions of temperature(21°C), humidity(60%), light and dark 
cycles(12h:12h). They were fed with food and water ad libitum (Crude proteins 21%, 
Crude fat 3,8%, Crude fibre 4,4%, Crude ashes 6,7%) for the first 6 weeks of life then 
ad libitum (Crude proteins 20%, Crude fat 3,5%, Crude fibre 4,9%, Crude ashes 6,7%) 
for the following weeks. The experiments were performed in compliance with the 
standards of the Federation of European Animal Science Association (FEASA) and 
have been approved by the institutional animal care committee (Landesamt für 
Arbeitsschutz, Gesundheitsschutz und technische Sicherheit Berlin, Germany, No. 
G0099/03).  
 
4.5.2 Wild type mice 
The C57BL mouse was originally derived by Little in 1921. Today, it is one of the most 
widely used and most popular strains in animal research. 
C57BL/6 is classified as an inbred, which results from a crossing of no less than 20 
consecutive generations of brother-sister matings. This allows the offspring to possess 
both genetic and phenotypic uniformity. As with most inbred strains, reproductive 
performance is lowered, along with the general size of the mouse and its overall 
lifespan, in comparison to its outbred counter part. 
All mice (Jackson Laboratory, Bar harbor, ME, USA) (total n=54) were males of age 8-
16 weeks, with an average weight of 28-32 g. They were randomized into 6 cohorts; 
group 1: normal mice (negative control) without trauma, group 2: sham-operated mice 
without trauma, group 3: trauma, group 4: trauma with posttraumatic intra peritoneal 
(i.p.) injection of 0.4ml PBS (vehicle) t=1h, t= 4 and t=24, group 5: trauma with Crry-Ig 
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4.5.3 Negative control (nil) group 
For the assessment of the baseline characteristics in normal (untreated) animals, these 
mice (n=3) were kept under identical conditions as the sham-operated, head injured, 
injected and knockout animals, but no experimental procedure was performed. 
  
4.5.4 Sham-operated control group 
These mice (n=9) were kept under the same conditions as the other animals, underwent 
anaesthesia and scalp incision but no head injury or injection were performed. Sham-
operated mice were sacrificed for brain tissue extraction and neurological assessment 
at t=4h, 24h, 7 days and 4weeks. 
  
4.5.5 Trauma group 
These mice (n=9) were kept under identical conditions as the other animals, underwent 
anaesthesia, scalp incision and trauma but were not injected at all. They were 
decapitated at time-points t=4h, 24h, 7 days and 4weeks. 
 
4.5.6 Vehicle injected 
This group of mice (n=13) were used as control group for the Crry-Ig and anti factor B 
injected mice. They were exposed to the same circumstances as these mice but 
received a posttraumatic i.p. injection of 0.4ml PBS (vehicle) t=1h, 24 and 7days. They 
were killed at time points corresponding to the other injected mice.  
 
4.5.7 Crry-Ig injected mice 
The C57BL/6 mice (n= 10) were exposed to trauma and then injected posttraumatic i.p 
with recombinant Crry-Ig. 1 mg Crry-Ig per mouse was chosen as standard dose, which 
is in titrated range used in previous studies on other murine models of inflammation 
[296-298]. The systemic (i.p) route of administration and the time window of injection 
was selected based on the following rationale: (a) In this model, the BBB is breached as 
early as 1 h after trauma, peaking at 4 h, and persisting up to 24 h [96, 299]. This allows 
a “time window of opportunity” for peripherally administrated compounds to reach the 
intrathecal compartment and exert pharmacological effects in the inflamed CNS, as 
previously shown for other pharmacological agents [117, 300, 301] ;(b) The post 
traumatic systemic injection within 1h after injury represents an approach with potential 
clinical implications; (c) A previous study using a different model of murine 
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neuroinflammation has determined that i.p. route of administration of Crry-Ig is feasible 
and enables Crry-Ig-mediated anti-inflammatory effects in brain [296].In order to induce 
a continuing complement inhibition during the acute inflammatory phase in the first 
days, a protocol of repeated i.p. injections of 1mg Crry-Ig in 4ml PBS was defined for 
t=1h and t=24h after the induced trauma. The half-life of this compound was determined 
at t1/2=40h after systemic injection in the mouse [297]  The mice were sacrificed at time-
points t=4h, 24h, 7 days and 4weeks. 
 
4.6 Model of closed head injury (CHI) in mice 
We use a CHI model which was developed at first in Rat [302] and later established in 
mice [299] in which a new mechanical device was build, with a falling weight adjusted 
for the size and weight of the mouse. The mouse model has been used by Esther 
Shohami’s group in various studies[120, 303-308]. Mice were anaesthetised using 
isoflurane for about 1 min., the skin covering there skull was longitudinal incised and 
retracted as to expose the skull. The head was manually fixed at the bottom of the 
impact device (B) (Fig. 10) and Focal trauma was induced to the left hemisphere, 2 mm 
lateral to the midline in the midcoronal plane, using an electric weight-drop device with a 
metal rod (A) of 333 g, falling from a height of 2 cm. The chosen height is maintained by 
an electric lock (D) controlled by a foot-touch switch (E). The impacting rod was 
supplemented with a silicone tip(C) of 3 mm diameter at its end, in order to avoid 
penetrating skull fractures.  
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Figure 10. Schematic di Shohami et al.) metal rod (A); 
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system[299]. It was reduced to 10 “essential” parameters which assess motor function, 
alertness, balancing and physiological behavior of each mouse. 
One point is awarded for failing to perform a particular task and zero points for 
succeeding (Table 5). The NSS was assessed at time-points1 hour, 4 hours, 24 hours 
and 7 days after trauma. Evaluation of task performance was performed by two 
investigators who were blinded about the animal groups. A maximal NSS of 10 points 
indicates severe neurological dysfunction, with failure of all tasks, whereas a score of 
zero is achieved by healthy uninjured mice. When a mouse was dead, it was excluded 
from the NSS evaluation. 
Task Description Points  Failure / success 
Exit circle Ability and initiative to exit a circle of 30 cm diameter (time limit: 3 minutes) 1 / 0 
Mono-/Hemiparesis Paresis of upper and/or lower limb of the contralateral side 1 / 0 
Straight walk Alterness, initiative, and motor ability to walk straight, once the mouse is put on the floor 1 / 0 
Startle reflex Innate reflex: the mouse will bounce in response to a loud hand clap 1 / 0 
Seeking behavior Physiological behavior as a sign of interest in the environment 1 / 0 
Beam balancing  Ability to balance on a beam of 7mm width for at least 10 seconds 1 / 0 
Round stick balancing Ability to balance on a beam of 5mm width for at least 10 seconds 1 / 0 
Beam walk: 3 cm Ability to cross a 30 cm long beam of 3 cm width 1 / 0 
Beam walk: 2 cm Same task, increased difficulty on a 2 cm wide beam 1 / 0 
Beam walk: 1 cm Indem, increased difficulty on a 1 cm wide beam 1 / 0 
MAXIMAL SCORE   10 
 
Table 5. Neurological Severity Score (NSS) for mice 
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4.8 Western Blot 
4.8.1 Homogenization (emulsification) of Mice’s Brain 
All steps are carried out on ice. The brains from Sham as well as trauma animals are 
cut into left and right hemisphere and placed in a 14ml test tube. 3ml lyses buffer (Table 
6) is added to the test tube and the brain is dispersed on level 5, 3 X 10 seconds (Ultra 
Turrax T18, IKA). Then centrifuged at a speed of 13000 x g for 15min. in a Beckman 
Centrifuge, Rotor JA25.1. The Probes are aliquoted and stored in -20°C. 
Chemical amount End concentration
Tris-HCl (1M pH 7,5)     100 µl  0.01M 
NaCl (3M)                          480 µl  0.144M 
SDS  (10%) 500 µl  0,5% 
Nonidet P40 50   µl  0,5% 
Aprotinin Tyrasylol   10   µl  10µg/ml 
Leupeptin (1mg/ml) 100 µl  10µg/ml 
Pepstatin (0.5mg/ml) 100 µl  5µg/ml 
PMSF (100mM in DMSO)        100 µl  1mM 
Deionized water 8,5 ml   
 
Table 6. Lysis buffer (10ml) 
 
4.8.2 Protein quanitation BCA (bicinchoninic acid) Protein Assay Reagent:  
A series of dilutions was prepared from 2 mg/ml BSA (stem solution) in Lysis buffer: 
1500, 1000, 750, 500, 250, 125, 25 und 0 g/ml BSA. The protein probes were diluted 
1:10 in lysis buffer. The series of dilutions were pipetted as well as the unknown probe 3 
times, each 10µl in a 96 well microplate. Reagent A (196µl/probe) and reagent B 
(4µl/probe) were mixed together then 200µl were added to each probe. The probes 
were incubated for 30min. in 37°C and then measured with spectrophotometer set to 
550 nm.  60µg is divided by the given value as to calculate the amount of protein to be 
loaded into wells formed in the gel using a well-forming comb.  
 
4.8.3 Discontinuous [1] SDS-Page 
Sodium dodecyl sulfate (SDS)-Polyacrylamide gel electrophoresis (Page) separate the 
denatured proteins by molecular weight [1].The proteins runs toward the positive pole 
through stacking (upper) gel to concentrate the large sample volume and then through 
separating (lower) gel. The molecular weight of unknown proteins can be determined 
with the help of blotting protein standards. 
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The Gels are prepared in a Mini-protean II electrophoresis cell (BIO RAD) where 
TEMED und APS are added directly before the solution is poured. At first the separating 
gel (Table 9; Table 10) is poured till 1 cm below the teeth of the comb and covered with 
deionized water. After polymerisation (30 minutes), the water is poured out, the area 
above the separating gel is dried with professional wipes (kimwipes) and stacking gel 
(Table 11) is poured. 
Chemical Amount 
Tris-Base (0.64 M)  38.5 g 
Tris-HCl(0.12 M) 9.3 g 
SDS(0.2%)  1.0 g 
adjust pH to 8.8 
make to 500 ml with deionized water   
Table 7. Separating gel buffer  
 
Chemical Amount
Tris-Base(0.33 M) 19.7 g 
SDS(0.2%) 1.0 g 
adjust pH to  6.8 
make to 500 ml with deionized water   
Table 8. Stacking gel buffer 
 
Chemical Amount
30% Acrylamid/Bis 37,5:1(2.6 % C) 4 ml 
Separating gel buffer 5 ml 
Deionized water 890 µl 
TEMED 10 µl 
10% ammonium persulfate 100 µl 
Table 9. Separating gel 12% (10ml)    
 
Chemical Amount
30% Acrylamid/Bis 37,5:1(2.6 % C) 5 ml 
Separating gel buffer 5 ml 
Deionized water - 
TEMED 10 µl 
10% ammonium persulfate 100 µl 
Table 10 Separating gel 15% (10ml) 
 
Chemical Amount
30% Acrylamid/Bis 37.5:1(2.6 % C) 890 µl 
Stacking gel buffer 2.5 ml 
Deionized water 1.7 µl 
TEMED 10 µl 
10% ammonium persulfate(APS) 50 µl 
Table 11 Stacking gel 5% (5ml) 
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A comb with 10 teeth is placed in the stacking gel, the gel is allowed to polymerize (30 
minutes) then the comb is removed by pulling it straight up slowly and gently. 
The samples are prepared from proteins samples (60µg) and lysis buffer. Probe buffer 
(Table 12) is added at a ratio 3:1 and heated at 95°C for 5 minutes as to denaturize the 
proteins. During this time the upper buffer chamber is assembled and the wells are 
rinsed with electrode buffer (Table 14). The samples and a protein standard (Table 13) 
are loaded using a Hamilton syringe, which is inserted to about 1mm from the well 
bottom before delivery. The electrophoresis runs at 80 volts for 30 minutes then at 120 
volts for 90 minutes.   
Chemical Amount
Tris-HCl, pH 6,8 2,5ml 
SDS 0,2g 
Glycerin 4ml 
-Mercaptoethanol (always added 
fresh) 2ml 
Bromphenolblau 4mg 
Deionized water 1,5ml 
Table 12. Probe buffer 4x (10ml) 
 
Protein Standards Amount 
Kaleidoscope Polypeptide Standards 10µl 
Precision Plus Protein Standards   5 µl 
Table 13. Protein standards 
 
Chemical Amount
Tris-Base 15.5 g 
Glycin 72.0 g 
SDS(10%) 50 ml 
make to 5 litres with deionized water   
Table 14. Electrode buffer (5l) 
 
4.8.4 Protein transfer 
The transfer Step (Western blot) involves moving and immobilizing the proteins from the 
SDS- polyacrylamide gel to a nitrocellulose membrane as to be more accessible and 
quantitatively detected. The 1st antibody binds specifically to the proteins and the 2ry 
antibody (labelled with horseradish peroxidase HRP) binds to it. The 2ry antibody can 
be detected visually through the conversion of a substrate to a colored precipitate at site 
of antibody binding.  
The membrane and the filter paper are cut 8.5cm x 5.3cm and soaked with the fibre pad 
and gel in transfer buffer (Table 15). The gel sandwich in Mini Trans-Blot Cell Assembly 
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(Bio-Rad) is prepared in the following order: cassette with the white side down, fibre 
pad, 2 filter papers, membrane, gel, 2 filter papers, and fibre pad. 
Chemical Amount
Electrode buffer  500ml 
Methanol 200ml 
Deionized water  300ml 
Table 15. Transfer buffer (1l) 
 
Gloves are used to prevent contamination and air bubbles are removed before the 
cassette is firmly closed. The cassette is placed in module and the tank is filled 
completely with buffer. The tank is placed in ice and a standard stir bar is added as to 
maintain an even buffer temperature and ion distribution in the tank. The blot is run for 2 
hours at 100 volts using a powerpac power supply (Bio-Rad). Afterwards, the 
membranes are placed in glass bowls, stained with Ponceau S and scanned. 
Then they are washed with PBS-Tween (0.05%) (Table. 16) till the stain disappears. 
The nitrocellulose membranes are blocked for immunolabeling by overnight incubation 
at 4°C refrigerator or 1 h at room temperature using 20 ml 3% or 5% (depending on the 
antibody) non fat dry milk in PBS-Tween (0.05%). 
Chemical Amount
PBS (phosphate-buffered saline) 9.55g 
Tween-20 500µl 
make to 1 litre with deionized water   
Table 16. PBS-Tween (0.05%) 
 
After incubation with first antibody and washing 3 x 5min. with 10 ml PBS-Tween 
(0.05%), the membranes are incubated with the second antibody and then washed 
again 3 x 5min. with 10 ml PBS-Tween (0.05%) and 1 x 5min with 10ml PBS (Table 17). 
10 ml of the ECL developing solution is prepared and the membranes are incubated for 
1 min, placed between 2 transparency films (without air bubbles) and covered with 
hyperfilm. The exposure time varies from 1 sec. till 2h depending on the signal.  
Chemical Amount
PBS 9.55 g 
make to 1 litre with deionized water   
Table 17. PBS 
 
If the membranes have to be incubated with another antibody, they are washed 30 min. 
with transfer buffer, 10 min. with PBS/Tween(0.05%), blocked overnight and the new 
first antibody is added the following morning. 
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4.8.5    Protein staining 
4.8.5.1 Ponceau S red stain 
The Ponceau S red stain was regularly performed to confirm that equal amounts of 
protein were loaded in each lane. The nitrocellulose membrane was taken after protein 
transfer, placed in a glass bowl, 10ml Ponceau were added and then placed over the 
shaker for 5 minutes. Afterwards the membrane is cleaned from all gel remnants, 
washed 5 minutes with PBS/Tween (0.05%) over shaker and then scanned. 
The stain could be used 4 or 5 times before getting rid of it.  
    
4.8.5.2 Coomasie blue stain 
The coomasie blue protein staining was also done frequently as to prove that equal 
amounts of protein are loaded in each lane. The SDS-Page is taken carefully after 
complete separation of the denatured proteins by molecular weight using 
electrophoresis and placed in a glass bowl. 50 ml of coomasie blue solution (Table 18) 
was poured to the gel and left on the shaker overnight. The gel is washed with water-
methanol (4:1) solution till the background is clear. The gel is scanned afterwards and 
the strength of the protein bands is interpreted using Tina (Fuji) computer program. 
Chemical Amount
concentrated coomasie blue 20 ml 
Methanol 20 ml 
Deionized water 60ml 
Table 18. Coomasie blue solution.   
 
4.9 Real-time RT-PCR: 
Intracerebral expression of neuroprotective genes of interest was assessed by semi-
quantitative two-step real-time RT-PCR using commercially available and custom-made 
murine-specific primers (Table). Homogenization of brain tissue samples was performed 
on ice in 2 ml of Qiazol® buffer (Qiagen, Hilden, Germany) per hemisphere, using an “Ultra 
TURRAX T25 basic“ homogenizer (IKA Werke, Staufen, Germany). RNA was isolated by 
phenol-extraction and purified using RNeasy® Mini-kits (Qiagen) and RNA concentrations 
were measured using a spectrophotometer (Bio-Rad, Munich, Germany). The quality of 
RNA extraction was verified by bioanalyzer (2100 Bioanalyzer, Agilent Technologies, Palo 
Alto, CA, USA). From each brain hemisphere, 2 g RNA were used for generation of cDNA 
(complementary DNA) templates using random nonamer and oligo-dT16mer primers 
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(Operon Biotechnologies, Cologne, Germany) with Omniscript® kits (Qiagen), according to 
the manufacturer’s instructions. Real-time RT-PCR was performed using validated 
commercially available and custom designed primer-probe® (Qiagen) sets (Table 2) and 
optimized protocols on the Opticon® real-time PCR Detection System (Bio-Rad). To avoid 
amplification of contaminated genomic DNA, half of the murine primers were designed to 
hybridize to the 3' end of one exon and the other half to the 5' end of the adjacent exon. All 
probes were verified by 3% agarose gel electrophoresis. For quantification of gene 
expression levels, GAPDH amplicons were generated and used as house-keeping internal 
control gene. Relative gene expression levels are expressed in relation to the 
corresponding GAPDH gene expression levels. 
 
4.10 Immunohistochemistry 
For assessment of neuronal morphology, integrity, and apoptosis, extracted mouse brains 
were snap-frozen in liquid nitrogen, embedded in OCT compound (Sakura Finetek, 
Torrance, CA) and stored at -80oC until used for analysis. Six to eight-micrometer thick 
coronal tissue sections were cut with a cryostat at -20°C. For immunohistochemistry, slides 
were fixed in acetone and then analyzed by a standard biotin/avidin/peroxidase technique 
with DAB (diaminobenzidine)-tetrahydrochloride as chromogen (Vector, Burlingame, CA), 
as previously described [191, 309]. The following primary antibodies were used as cell-
markers: monoclonal anti-NeuN, at a titrated dilution of 1:2,000 (Chemicon, Hampshire, 
UK) for neurons; polyclonal rabbit anti-GFAP (glial fibrillary acidic protein), 1:100 (Shandon 
Immunon, Pittsburgh, PA, USA) for astrocytes; monoclonal rat anti-CD11b, 1:100, 
(Accurate Chemical, Westbury, NY, USA) for microglia; Non-immunized IgG (Vector) was 
used as negative control at equal dilutions as the omitted specific antibody. 
 
4.11 TUNEL 
To determine the extent of intracerebral neuronal cell death, TUNEL histochemistry was 
performed using a “Fluorescein In Situ Cell Death Detection Kit” (Roche Diagnostics 
GmbH, Mannheim, Germany), according to the manufacturer’s instructions, as previously 
described [96]. Briefly, slides were dried for 30 min followed by fixation in 10% formalin 
solution at RT. After washing in PBS (three times for 3 min), sections were incubated in 
ice-cold ethanol-acetic acid solution (2:1) for 5 min at -20°C. Thereafter, they were washed 
in PBS and incubated in a permeabilization solution with 3% Triton X-100 in PBS for 60 
min at RT, then incubated with the TdT enzyme in a reaction buffer containing fluorescein-
 44
dUTP for 90 min at 37°C. Negative control was performed using only the reaction buffer 
without TdT enzyme. Positive controls were performed by digesting equal brain sections 
with DNase grade I solution (500U/ml; Roche) for 20min at RT and always kept separate 
from the other samples thereafter. After labelling, the sections were washed again in PBS 
and to visualize the unstained (TUNEL-negative) cells, the sections were covered with 
Vectashield mounting medium for fluorescence with DAPI (Vector). All samples were 
evaluated immediately after staining using an Axioskop 40 fluorescence microscope 
(Zeiss, Germany) at 460 nm for DAPI and 520 nm for TUNEL fluorescence and analyzed 
by Alpha digi doc 1201 software (Alpha Innotech, San Leandro, CA, USA). 
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5. Results 
5.1 Neurological outcome 
With regard to the neurological outcome, Crry-Ig-treated mice showed a significantly 
attenuated neurological impairment for up to 7 days after trauma compared to vehicle-
injected control mice, as determined by a standardized 10-parameter NSS (P < 0.05 vs. 
vehicle-injected TBI mice, repeated measures ANOVA (analysis of variance), (Fig. 11).  
 
Figure 11.
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 Crry-Ig mediates improved neurological recovery after experimental TBI in mice[191]. 
Based on a standardized 10-parameter Neurological Severity Score (NSS), Crry-Ig-treated mice showed 
a significantly attenuated neurological impairment from 4h to 7 days after trauma compared to vehicle-
injected control mice. The scores were evaluated by two independent investigators who were blinded 
about the groups. Data are shown as median levels of n=6 mice per group and time-point, except for “nil“ 
controls, n=3 per time-point. *P < 0.05, Crry-Ig vs. vehicle; repeated measures ANOVA. 
 
In addition, when the individual tasks of the NSS (as depicted in table 5) were split up 
for analysis, the percentage of mice failing single task performances was significantly 
higher in the vehicle- as opposed to the Crry-Ig-treated groups at all time-points 
assessed[191]. A representative example is shown for the task “beam walk 3 cm” in 
Fig. 12. 
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Figure 12. Single Task Performance [191]. This figure shows representative results of differen
single task performance between the vehicle and Crry-Ig-injected groups, as shown for the in
“beam walk 3 cm”. Graph bars represent the percentage of mice which failed the task, as determin
two independent, blinded investigators. TBI; traumatic brain injury. 
 
5.2 Complement regulatory genes 
Intracerebral expression of neuroprotective genes of interest was assessed by
quantitative real-time RT-PCR analysis of brain tissue homogenates using mouse-
specific primers (Table 19
ces in 
dividual task 
ed by 
 
) [191]. Baseline expression of the complement regulatory 
genes for C1-Inh, CD55, and CD59 was determined in brain homogenates from 
untreated normal male mice of the C57BL/6 strain (“nil” group, n=3 per gene, Fig. 13). 
 Gene ID  
 
Order No. Length of Primer Probe GenBank 
Qiagen # at NCBI * Accession 
No. 
amplicon sequence Sequence 
GAPDH¶ 14433 
 
NM_008084 136 bp commercially available Genexpression Assay QuantiTect  Mm_GAPD 241012 
Bcl-2 12043 
 
NM_009741 
NM_177410 
 
118 bp commercially available Genexpression Assay QuantiTect  Mm_Bcl-2 241118 
CD55 13136 
 
NM_010016 96 bp 
CAGTTAAAGTTTCAGC
AACCCACTGTGTTAGG
CTCTCCTTTGT 
CCAAGACAACAGT*ACG custom made 
CD59a 12509 
 
U60473 
NM_007652 
 
124 bp 
GACTCTAAGATTGCAG
ATTTGGGAAACAGTGG
TAGCATGTGAGG 
TGGCTGTGT*T*CTGT*T*C custom made 
C1-Inh 12258 
 
NM_009776 134 bp 
AACTTAGAACTCATCAA
CACCTGTTATCTTCCAC
TTGGCACTC 
ACACCTGCCTCGTCCT custom made 
Table 19. Murine primer sequences used for real-time RT-PCR analysis of intracerebral gene 
expression [191]. 
* NCBI = National Center for Biotechnology Information (www.ncbi.nlm.nih.gov/genome/guide/mouse/) 
# www.qiagen.com 
¶ housekeeping gene 
 
In sham-operated control mice (n=6 per gene and time-point), a slight but non-
significant increase of C1-Inh expression was noted between 4 hours to 7 days (P > 
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0.05 vs. “nil“, unpaired Student’s t-Test; Fig. 13). In contrast, the sham procedure led to 
a significant upregulation of the complement regulatory genes for CD55 and CD59, as 
compared to baseline expression (P < 0.05 vs. “nil“; Fig. 13)[191]. Experimental brain 
injury and vehicle control injection at 1h (400 l PBS) induced a further up-regulation of 
CD59 mRNA expression within 4 h after trauma (P < 0.05 vs. sham; Fig. 13), but not at 
later time-points. The gene expression levels of CD55 were not altered at any time-point 
in the trauma/vehicle group, compared to the sham cohort (P > 0.05) [191]. In contrast, 
the inhibitor of the classical pathway of complement activation, C1-Inh, showed 
significantly increased mRNA levels at all time-points up to 7 days in the trauma/vehicle 
group, compared to sham-operated mice (P < 0.05; Fig. 13)[191].  
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Figure 13. Regulation of posttraumatic intracerebral gene expression by Crry-Ig, as determined b
quantitative two-step real-time RT-PCR [191]. RNA was extracted from homogenized murine br
defined time-points. The murine primers for the complement regulatory genes C1-Inh, CD55, an
are shown in table 2. The technique for real-time RT-PCR analysis is described in detail in the 
section. Data are shown as mean levels SD from n=3 per gene in the “nil“ group and n=6 per ge
time-point in all other groups. *P < 0.05, sham vs. “nil“ and trauma/vehicle vs. sham; #P
trauma/Crry-Ig vs. trauma/vehicle; unpaired Student’s t-Test. TBI, traumatic brain injury. 
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Mice injected with 1 mg Crry-Ig one hour after trauma showed a significant up-
regulation of C1-Inh and CD55 gene expression levels by 4h after head injury, as 
compared to vehicle-injected controls (P < 0.01), whereas CD59 mRNA levels were not 
significantly elevated at 4h (P > 0.05)[191]. After 24h, both CD55 and CD59 genes 
showed a significant increase in the Crry-Ig group (P < 0.01 vs. vehicle control; Fig.13). 
The upregulation of CD55 and CD59 genes persisted from 24 h to 7 days. In contrast, 
C1-Inh mRNA levels were significantly suppressed at 24h in Crry-Ig-injected TBI mice, 
compared to the vehicle-injected animals (P < 0.01; Fig.13) [191]. A repeated Crry-Ig 
injection at 24h led to a continued down-regulation of C1-Inh mRNA for up to 7 days 
after trauma (P < 0.01 vs. vehicle control; Fig.13).  
 
5.3 Regulation of Bax and Bcl-2 expression in injured brains  
With regard to intracerebral expression and regulation of the mitochondrial anti-
apoptotic Bcl-2 gene, a slight but non-significant increase in mRNA levels was noted in 
sham-operated animals between 24 hours to 7 days, as compared to constitutive levels 
in normal mice (P > 0.05, unpaired Student’s t-Test; Fig.14A)[191]. Bcl-2 gene 
expression had a trend of increase at 4h and 24h and was significantly increased at 7 
days in the trauma/vehicle group (after a repeated injection at 24h), compared to sham-
operated animals (P < 0.05; Fig.14A). After injection of 1 mg Crry-Ig one hour after 
trauma, a significant up-regulation of Bcl-2 mRNA was detected by 4h after trauma, as 
compared to vehicle-injected controls (P < 0.01).[191] At later time-points, Bcl-2 gene 
expression levels remained elevated in the Crry-Ig vs. vehicle control group, albeit at 
non-significant levels (t=24h and 7 days, P > 0.05; Fig.14)[191].  
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Figure 14. Regulation of the mitochondrial anti-apoptotic mediator Bcl-2 at the mRNA and protein 
level, as determined by real-time RT-PCR (A) and Western blot analysis (B) [191]. RNA was 
extracted from homogenized murine brains at defined time-points. The primers used for the murine Bcl-2 
gene are shown in table 2. Data are presented as medians SD from n=3 per gene in the “nil“ group and 
n=6 per gene and time-point in all other groups. *P < 0.05, TBI vehicle vs. sham; #P < 0.01, TBI Crry-Ig 
vs. TBI vehicle; unpaired Student’s t-Test. Western blot analysis was performed on murine brain 
homogenates using a specific monoclonal anti-mouse Bcl-2 antibody and a non-radioactive
chemoluminescence assay, as described in the Methods section. Equal protein amounts (60 g per lane) 
were loaded on SDS-PAGE and consistent blotting was confirmed by Ponceau staining (not shown) or by 
control blotting with -actin. Western blot experiments were performed in duplicate in order to ensure 
reproducibility of the results. TBI, traumatic brain injury. Positive control: Bcl-2 transfected melanoma 
cells. 
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By Western blot analysis, Bcl-2 protein levels were detected at constitutive levels in 
normal untreated mice (Fig.14B). Experimental TBI alone or in combination with vehicle 
injection (400 l PBS i.p.) induced slightly increased intracerebral Bcl-2 protein levels, 
compared to normal mouse brain (Fig.14B) [191]. In contrast, the injection of Crry-Ig led 
to a strong induction of Bcl-2 protein in the injured mouse brain, as apparent in Fig.14B. 
In addition to the specific Bcl-2 band, which is confirmed by the positive control using 
Bcl-2 transfected melanoma cells (Fig.14B), a presumptive phosphorylation product 
splice of Bcl-2 [329] is detectable above the 26 kDa band in the TBI brains, with clearly 
increased levels after Crry-Ig injection, compared to TBI and vehicle injection or to TBI 
alone (Fig.14B) [191]. The intracerebral Bcl-2 protein levels were higher in the left 
hemisphere, which received the direct trauma, (Fig.15) than the right hemisphere. The 
intracerebral Bcl-2 protein levels were higher in the left hemisphere, which received the 
direct trauma, (Fig.15) than the right hemisphere. 
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Figure 15. Difference in Bcl-2 expression between left (LH) and right (RH) he
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The Bcl-2 level was lower in normal mouse brain (not injected nor operated) than in 
Sham operated mice (Fig.17). It tended to increase by 4h after trauma and was up-
regulated after Crry-Ig injection by 4h and 24h. In serum, the level of Bcl-2 was higher in 
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normal mouse than in sham-operated animals, where the level was high after trauma by 
4h in traumatized mice, vehicle as well as Crry-injected mice (Fig.17). By 24h the level 
of Bcl-2 sank in vehicle and Crry-injected mice. 
Figure 17. Bcl-2 expression during the 1st 24h after trauma in mice brain and serum 
 
In n=2, we could see that the level of Bcl-2 in serum was again higher in Trauma by 4h 
than by 24h in Crry-Ig injected mice (Fig.18). The level of Bcl-2 raised by 7 days post-
trauma, where the highest level was in Sham operated mice and the lowest level was in 
Crry-Ig injected mice. 
Figure 18. Level of Bcl-2 in serum (t=4h, 24h and 7days) 
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Bcl-2 level showed a trend to increase after injection of Crry-Ig by 4h (Fig.19A) vs. 
Vehicle injected mice, where the biggest difference was by 24h. 4 weeks post-trauma, 
the level of Bcl-2 is slightly higher in Vehicle-injected mice vs. Crry-Ig injected mice 
(Fig.19A).The strength of the signal produced by Bcl-2 and -Actin was analyzed using 
Tina 2.09 software (Raytest, Straubenhardt, Germany) and the relative expression of 
Bcl-2 in relation to -Actin was calculated and displayed (Fig.19B).  
Figure 19.
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The level of Bax-protein in brain was determined using Western Blot. The lowest level 
was in sham-operated mice at all time points. By t=4h the level of Bax increased slightly 
after Vehicle injection but showed a higher up-regulation after injection of Crry-Ig (Fig. 
16). By t=24h, the level of Bax- was notably elevated after Crry-Ig injection in 
comparison to vehicle injection, which was as well detected 7days post-trauma (Fig. 
16). The Bax-level was lower in normal mouse brain (neither injected nor operated) 
than in Sham operated mice (Fig.20). It tended to increase by 4h after trauma and was 
up-regulated after Crry-Ig injection by 4h and 24h. In serum, the level of Bax-couldn’t 
be detected (Fig.20). 
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Figure 20. Bax-
 
Bax-
 expression during the 1st 24h after trauma in mice brain and serum 
level showed a trend to increase after injection of Crry-Ig by 4h (Fig. 21A) vs. 
Vehicl , 
the level of
(Fig. 21A
e injected mice, where the biggest difference was by 24h. 4 weeks post-trauma
 Bax-is slightly higher in Vehicle-injected mice vs. Crry-Ig injected mice 
).The strength of the signal produced by Bax-and -Actin was analysed 
na 2.09 software (Raytest, Straubenhardt, Germany) and the relative 
on of Bax-in relation to -Actin was calculated and displayed (Fig. 21B
using Ti
expressi ). 
Figure 21. Expression of Bax- protein level (t=4h, 24h, 7days and 4 weeks) and the relative 
expression of Bax-in relation to -Actin. 
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A slight but non-significant increase in mRNA levels was noted in sham-operated mice 
between 24 hours to 7 days in comparison to constitutive levels in normal mice (Fig.22). 
The Bax gene expression tended to remain constant at different time points (t= 4h, 24h 
and 7days) in the vehicle group (Fig.22). The Bax mRNA was up regulation after 
injection of Crry at the different time points in comparison to Vehicle injected mice  
1.6
1.8
2.0
Figure 22. Regulation of the mitochondrial pro-apoptotic mediator Bax at the
determined by real-time RT-PCR  
 
5.4 Posttraumatic neuronal cell death 
Morphologically, hippocampal neurons in the Ammon’s horn (Cornu ammonis
 mRNA level, as 
; CA) 
layers 3 and 4 of the ipsilateral hemisphere showed a massive destruction of the 
microarchitecture and loss of normal morphology, such as the polygonal large body 
shapes of pyramidal neurons, within 4 hours after trauma in the vehicle-injected mice, 
as compared to “sham“-operated controls (Fig. 23, middle panels) [191]. In contrast, 
the Crry-Ig-injected mice showed clear histological signs of neuronal protection, since 
the highly vulnerable pyramidal neurons in the CA3/CA4 sublayers of the hippocampus 
were restored to similar morphological features as in the “sham“-operated group (Fig. 
23) [191].  
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Figure 23. Protective action of Crry-Ig against posttraumatic neuronal cell death in hippocampal CA3/CA4 
regions [191]. Male C57BL/6 mice (n = 3 per group) were killed 4 h after “sham” operation (left panel) or 
after i.p. injection 1 h after CHI with 400 μl PBS alone (vehicle control; middle panel) or with 1 mg Crry-Ig 
in 400 μl PBS (right panel). Determination of neuronal morphology and microarchitecture was performed 
by immunohistochemical staining of coronal cryosections with a monoclonal anti-NeuN antibody, as 
described in the Methods section. While “sham”-operated animals showed a normal neuronal morphology 
in the hippocampus (left panel), CHI resulted in a clear reduction and architectural destruction of the 
pyramidal neuron population mainly in the Ammon's horn CA3/CA4 regions, as shown for a 
representative vehicle-injected CHI mouse (middle panel). In contrast, the treatment with Crry-Ig after 
trauma clearly attenuated the neuronal cell loss in the corresponding hippocampal sublayers and partially 
restored the neuronal cell layer morphology in the CA3/CA4 sublayers (right panel). The bottom figures 
are a 10× magnification of the drawn insert in the upper figures (original magnifications: 40× vs. 400× in 
upper vs. bottom microphotographs, respectively). The asterisk marks the contusion zone in the left 
cortical hemisphere of the brain-injured animals. 
 
The extent of neuronal cell death is shown to be limited after the injection of Crry-Ig, 
where the number of TUNEL positive cells in the hippocampal CA3 region was much 
less by t=4h and 24h than in Vehicle injected mice (Fig.24).  
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Figure 24. Posttraumatic neuronal cell death in hippocampal CA3 region in sham operated mice 
and mice with Traumatic brain injury after vehicle and Crry-Ig injection, as determined by TUNEL 
histochemistry. The magnification is 400x 
 
In the ipsilateral cortical region of injured hemisphere, the Crry-Ig injection prevented 
the extension of neuronal cell death in comparison to the vehicle injected mice by t=4h 
and 24h (Fig.25), where the number of TUNEL positive cells was less.  
 
sham TBI (Crry-Ig)TBI (vehicle)
4h
24h
sham TBI (vehicle) TBI (Crry)
24h
4h
Figure 25. Posttraumatic neuronal cell death in the injured (left) cortical hemisphere with sham 
operated mice and mice with Traumatic brain injury after vehicle and Crry-Ig injection, as 
determined by TUNEL histochemistry. The magnification is 400x. 
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6. Discussion 
Neuroprotection from complement-mediated inflammatory damage to the brain 
represents a prevailing topic of research in neuroinflammatory and neurodegenerative 
diseases [56, 310-315]. In the present study, we assessed the effect of pharmacological 
complement inhibition at the C3 convertase level by exogenous administration of murine 
recombinant Crry-Ig on intracerebral gene expression profiles, the neurological 
outcome[191], regulation of apoptotic proteins and state of hippocampal neurons after 
experimental TBI. We demonstrate here for the first time, to our knowledge, that the 
posttraumatic pharmacological blocking of complement activation by Crry-Ig leads to a 
significantly increased neurological recovery after CHI in mice, as compared to vehicle-
injected control animals [191]. Furthermore, the neuronal subsets with highest 
vulnerability to head injury in the hippocampal layers [299, 300, 316, 317] were 
protected by Crry-Ig administration, as opposed to vehicle-injected brain-injured mice. 
The analysis of neuroprotective gene expression patterns in injured brains revealed that 
the systemic injection of Crry-Ig mediates an upregulation of complement regulatory 
genes (C1-Inh, CD55, CD59) and of the potent mitochondrial anti-apoptotic mediator 
Bcl-2, both at a gene and protein level, with differential expression kinetics of these 
mediators during the first 7 days after trauma[191]. The pro-apoptotic mediator Bax was 
up-regulated but to a lesser extent than Bcl-2 with a neuroprotective end effect as 
detected by anti-NeuN antibody staining and TUNEL histochemistry.  
In order to establish a pharmacological model with potential clinical relevance, we chose 
a peripheral route of administration (i.p.) during the “time window of opportunity” at one 
hour after trauma. This timing correlates with the potential for early therapeutic 
intervention in TBI patients [5] and with the time-frame of early BBB dysfunction in the 
present murine model system, thus allowing for a pharmacological compound to reach 
the intrathecal compartment after systemic injection, as previously determined for other 
pharmacological agents [117, 300, 301]. The penetration of the Crry-Ig compound into 
the intrathecal compartment after i.p. injection in mice was recently confirmed in a 
different setting of experimental neuroinflammation based on a model of murine lupus 
cerebritis [296].  The strategy of a repeated injection at 24h was previously established 
and shown to be effective for other neuroprotective drugs in this murine model[300, 
301]. In the present study, the injection of 1 mg Crry-Ig in 400 l PBS at 1h and 24h 
after trauma led to a significant complement inhibition in serum within 4h to 7 days 
compared to vehicle-injected controls. Thus, this dose regimen – which is in the titrated 
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range from previous studies on different models of inflammation in the mouse[296-298] 
– is functional in the in vivo setting of trauma-induced neuroinflammation in our model of 
experimental TBI.  
The extent of posttraumatic neurological impairment was determined in a blinded 
fashion using a previously characterized 10-parameter score (NSS) [96, 117, 300, 304]. 
This score has been shown to correlate with the severity of brain injury and the volume 
of injured brain tissue, as determined by MRI and histological analyses [304]. In the 
present study, the administration of Crry-Ig at 1h and 24h after head injury resulted in a 
significantly improved neurological outcome of brain-injured mice for up to 7 days, as 
compared to vehicle-injected control animals. This finding is consistent with previous 
data from the same model system, where transgenic mice with astrocyte-targeted 
overexpression of the Crry gene had a significantly decreased NSS within 1h to 4 
weeks after trauma, as compared to brain-injured wild-type littermates[192]. Thus, our 
present results provide a pharmacological extension of the “baseline“ data derived from 
the transgenic model [192] and affirm the feasibility of complement inhibition by Crry-Ig 
in experimental neurotrauma. 
In order to assess the potential molecular mechanisms underlying the Crry-Ig-mediated 
beneficial effects on neurological scores, we further investigated the expression and 
regulation of candidate protective genes in the injured mouse brain [191]. These include 
Bcl-2, a crucial anti-apoptotic mediator in the mitochondria [248], as well as selected 
complement regulatory molecules, such as C1-Inh, a major control molecule of the 
classical pathway of complement activation, DAF/CD55, a membrane-bound inhibitor at 
the C3 level of complement activation, and CD59, a “key“ regulator of terminal 
complement pathway MAC/C5b-9 deposition in brain tissue [318-320] [319-324]. 
Furthermore, we investigated Bax, a critical pro-apoptotic mediator (Deckwerth 1996) 
on the gene expression level and protein synthesis and finally the end effect of Crry-Ig 
on apoptosis and neuronal cell death. We found a differential regulation and differing 
kinetics of intracerebral gene expression after Crry-Ig administration. Interestingly, 
“sham“ operation alone (i.e. isoflurane anesthesia and scalp incision) led to a significant 
induction of complement regulatory genes for CD55 and CD59, as compared to 
baseline constitutive gene expression levels in untreated mice[191]. It was previously 
shown that complement gene expression in the murine brain is in part affected by basic 
procedures such as “sham“ operations under anesthesia, as described for C5aR mRNA 
expression on neurons [309]. Since this effect was not observed for every gene 
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investigated in the present study, we hypothesize that CD55 and CD59 mRNA‘s have a 
lower threshold for induction by anesthetic drugs, such as isoflurane, as opposed to the 
genes for C1-Inh or Bcl-2. The mechanisms of anesthesia- or “sham“-operation-induced 
gene regulation in the CNS are unclear at present and remain to be further investigated. 
After trauma, the genes for C1-Inh and CD55 were significantly upregulated within 4h in 
the Crry-Ig-injected group, as compared to vehicle-injected controls. The CD59 gene 
showed a slightly differing kinetic with a peak at 24 h, whereas the CD55 gene 
remained significantly elevated above the vehicle controls for up to 7 days after TBI. In 
contrast, the C1-Inh gene was significantly suppressed at the later time-points (24h and 
7 days) compared to vehicle-injected mice. These data suggest that Crry-Ig modulates 
its anti-complement effects not only by direct inhibition of C3 convertases [325, 326], but 
also by indirect upregulation of other complement-regulatory genes (C1-Inh, CD55, 
CD59).  
Apoptotic neuronal cell death contributes to secondary neurodegeneration after brain 
injury [95, 327]. Bcl-2 represents one of the crucial mitochondrial regulators of apoptosis 
and a potent neuroprotective molecule [248, 328]. In the present study, we detected a 
posttraumatic upregulation of Bcl-2 mRNA within 7 days, which was further induced in 
the Crry-Ig-treated group as early as 4h after trauma. Crry-Ig-mediated increase in 
intracerebral Bcl-2 expression was furthermore confirmed at the protein level by 
Western blot analysis. An extra band above the specific 26 kDa Bcl-2 band (Fig. 14B) 
may result from phosphorylation of Bcl-2, a phenomenon which was recently described 
as a new molecular mechanism of regulation of apoptosis [329]. These data suggest 
that Bcl-2 may exert beneficial mechanisms of action with regard to protection from 
complement-induced neuronal apoptosis after brain injury [95, 150].  
Bax represents a key pro-apoptotic modulator [248]. Interestingly, we detected as well a 
relative posttraumatic up-regulation of Bax mRNA within 7days which was further 
induced in the Crry-Ig injected mice. The synthesis of Bax protein was stimulated 
posttraumatic as detected by western blot but the Bcl2/Bax ratio was in favor of Bcl-2 
having a neuroprotective end effect. 
The neuroprotective effect of Crry-Ig was confirmed by the clear histological signs of 
neuroprotection after staining of hippocampus and cortex with anti-NeuN antibody. 
The TUNEL histochemistry showed a limited number of TUNEL positive cells in the 
Crry-treated mice vs. Vehicle-treated mice, which further proved the defensive effect of 
Crry-Ig against neuronal cell death and apoptosis. 
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Studies by other groups have previously addressed the potential of pharmacological 
complement inhibition in different TBI models [36, 186, 200]. However, these studies 
should be interpreted with caution due to drawbacks in the experimental designs as well 
as questions regarding the potential clinical relevance of the results [191].  Specifically, 
previous models used human complement inhibitors in a rat trauma model due to the 
lack of species-specific reagents at the time [36]. Furthermore, in these previously 
published studies the complement inhibitor was injected before the injury, a protocol 
which cannot be extrapolated into a clinically relevant setting [36, 186, 200]. Finally, in 
contrast to the standardized fluid-percussion injury model [36, 200] and our model of 
CHI [117, 299-301], the experimental cryoinjury model [186] does not have a clinical 
relevance since it does not represent an injury pattern which occurs in TBI patients. The 
data from the present study, using a species-specific and highly potent complement 
inhibitor at the level of the C3 convertase of all complement activation pathways, 
provides a strong rationale for pharmacological complement inhibition in the early phase 
after head injury and provides the basis for future studies on the exact cellular and 
molecular mechanisms of neuroprotection mediated by Crry-Ig [191].   
One drawback of the present study is the lack of a demonstration of direct Crry-Ig-
mediated effects in the injured brain. It may well be that the blocking of anaphylatoxin 
C5a formation by Crry-Ig after head injury prevents chemotaxis of potentially neurotoxic 
peripheral immune cells, such as neutrophils, across the BBB. This was previously 
shown in a rat model of head injury by the use of sCR1, a human recombinant inhibitor 
of complement C3 convertases [36]. Thus, whether the observed beneficial outcome of 
complement inhibition is due to direct or indirect mechanisms of action by Crry-Ig 
remains to be determined in future studies [191]. 
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8. Abbreviations 
 
aa amino acid 
AD Alzheimer’s disease 
ADP adenose-diphosphate 
ANOVA analysis of variance 
Apaf-1 apoptosis activating factor 1 
APR acute-phase response 
ATP adenosine triphosphate 
BBB blood-brain barrier 
BCA bicinchoninic acid 
Bcl-2 B-cell leukemia/lymphoma-2 
BDCF brain-derived chemotactic factor 
BH Bcl-2 homology 
C Complement 
C1-INH C1 inhibitor 
C3aR / C5aR C3a receptor / C5a receptor (CD88) 
C4-bp C4-binding protein  
CCI Controlled cortical impact 
cDNA complementary DNA 
CHI closed head injury 
CGNs cerebellar granule neurons 
CNS central nervous system 
CPP cerebral perfusion pressure 
CR complement receptor 
CRP C-reactive protein 
Crry Complement receptor-related protein y 
CSF cerebrospinal fluid 
Cyt c cytochrome c 
DAF decay-accelerating factor (CD55) 
DAB diaminobenzidine 
DAI diffuse axonal injury 
DNA deoxy-ribonucleic acid 
EAA excitatory amino acid 
EAE experimental autoimmune encephalomyelitis 
EC endothelial cells 
FasL Fas (CD95)-ligand 
FEASA Federation of European Animal Science Association 
FPI Fluid percussion injury 
GFAP glial fibrillary acidic protein 
GPI glycosyl-phosphatidyl-inositol 
HRP horseradish peroxidase 
ICP intracranial pressure 
Ig-Crry immunoglobulin G1-Crry 
IL / IFN interleukin / interferon 
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i.p intra peritoneal 
LH left hemisphere 
MaBP Mannose-binding protein 
MBL mannose-binding lectin 
MAC membrane attack complex (C5b-9) 
MCP membrane cofactor protein (CD46) 
MO monocytes 
MS multiple sclerosis 
NGF nerve growth factor 
NK natural killer 
NO nitric oxide 
NOS nitrogen oxide synthase 
NSS Neurological Severity Score 
Page polyacrylamide gel electrophoresis 
PARP poly ADP-ribosyl DNA polymerase 
PBS phosphate-buffered saline 
PCD programmed cell death (apoptosis) 
PCR polymerase chain reaction 
PI-PLC phosphatidyl-inositol-specific phospholipase C 
PKA protein kinase 
PMN polymorphonuclear leukocytes 
PTP permeability transition pore 
RH right hemisphere 
RNA ribonucleic acid 
ROS reactive oxygen species 
RT-PCR reverse-transcription polymerase chain reaction 
SAS subarachnoid space 
SCI spinal cord injury 
sCR1 soluble complement receptor type 1 
sCrry soluble Crry 
SDS-page sodium dodecyl sulfate polyacrylamide gel 
SPF specific pathogen-free 
TBI traumatic brain injury 
TdT terminal deoxynucleotidyl transferase 
TNF(R) tumor necrosis factor (receptor) 
TUNEL terminal deoxynucleotidyl transferase dUTP nick end labeling 
VCP Vaccinia virus complemet control protein 
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